




Handbook of COVID-19 Prevention and Treatment

*The First Affiliated Hospital, Zhejiang University School of Medicine
Compiled According to Clinical Experience*



VISIT...

LANZAROTE
Caliente.COM



Editor's Note:



Faced with an unknown virus, sharing and collaboration are the best remedy.

The publication of this Handbook is one of the best ways to mark the courage and wisdom our healthcare workers have demonstrated over the past two months.

Thanks to all those who have contributed to this Handbook, sharing the invaluable experience with healthcare colleagues around the world while saving the lives of patients.

Thanks to the support from healthcare colleagues in China who have provided experience that inspires and motivates us.

Thanks to Jack Ma Foundation for initiating this program, and to AliHealth for the technical support, making this Handbook possible to support the fight against the epidemic.

The Handbook is available to everyone for free. However, due to the limited time, there might be some errors and defects. Your feedback and advice are highly welcomed!

Prof. Tingbo LIANG

Editor-in-Chief of the Handbook of COVID-19 Prevention and Treatment
Chairman of The First Affiliated Hospital, Zhejiang University School of Medicine

A stylized handwritten signature in black ink, consisting of three main characters: '梁廷波' (Liang Tingbo).

Foreword

This is an unprecedented global war, and mankind is facing the same enemy, the novel coronavirus. And the first battlefield is the hospital where our soldiers are the medical workers.

To ensure that this war can be won, we must first make sure that our medical staff is guaranteed sufficient resources, including experience and technologies. Also, we need to make sure that the hospital is the battleground where we eliminate the virus, not where the virus defeats us.

Therefore, Jack Ma Foundation and Alibaba Foundation have convened a group of medical experts who have just returned from the frontlines of fighting the pandemic. With the support of The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), they quickly published a guidebook on the clinical experience of how to treat this new coronavirus. The treatment guide offers advice and reference against the pandemic for medical staff around the world who are about to join the war.

Thanks to the medical staff from FAHZU. While taking huge risks in treating COVID-19 patients, they wrote down their treatment experience day and night in this Handbook.

Over the past 50 days, 104 confirmed patients have been admitted to FAHZU, including 78 severe and critically ill ones. Thanks to the pioneering efforts of medical staff and the application of new technologies, to date, we have witnessed a miracle. No staff is infected, and there is no missed diagnosis or patient deaths.

Today, with the spread of the pandemic, these experiences are the most valuable sources of information and the most important weapon for medical workers on the battlefield. This is a brand-new disease, and China was the first to suffer from the pandemic. Isolation, diagnosis, treatment, protective measures, and rehabilitation have all been started from scratch, but we hope that with the advent of this Handbook doctors and nurses in other affected areas can learn from our experience when entering the battlefield and they won't have to start from zero.

This pandemic is a common challenge faced by mankind in the age of globalization. At this moment, sharing resources, experiences and lessons, regardless of who you are, is our only chance to win. Because the real remedy for epidemics is not isolation, but cooperation.

This war has just begun.

Contents

Part One Prevention and Control Management

I. Isolation Area Management.....	1
II. Staff Management.....	4
III. COVID-19 Related Personal Protection Management.....	5
IV. Hospital Practice Protocols during COVID-19 Epidemic.....	6
V. Digital Support for Epidemic Prevention and Control.....	16

Part Two Diagnosis and Treatment

I. Personalized, Collaborative and Multidisciplinary Management.....	18
II. Etiology and Inflammation Indicators.....	19
III. Imaging Findings of COVID-19 Patients.....	21
IV. Application of Bronchoscopy in the Diagnosis and Management of COVID-19 Patients.....	22
V. Diagnosis and Clinical Classification of COVID-19.....	22
VI. Antiviral Treatment for Timely Elimination of Pathogens.....	23
VII. Anti-shock and Anti-hypoxemia Treatment.....	24
VIII. The Rational Use of Antibiotics to Prevent Secondary Infection.....	29
IX. The Balance of Intestinal Microecology and Nutritional Support.....	30
X. ECMO Support for COVID-19 Patients.....	32
XI. Convalescent Plasma Therapy for COVID-19 Patients.....	35
XII. TCM Classification Therapy to Improve Curative Efficacy.....	36
XIII. Drug Use Management of COVID-19 Patients.....	37
XIV. Psychological Intervention for COVID-19 Patients.....	41
XV. Rehabilitation Therapy for COVID-19 Patients.....	42
XVI. Lung Transplantation in Patients with COVID-19.....	44
XVII. Discharge Standards and Follow-up Plan for COVID-19 Patients.....	45

Part Three Nursing

I. Nursing Care for Patients Receiving High-Flow Nasal Cannula (HFNC) Oxygen Therapy.....	47
II. Nursing Care in Patients with Mechanical Ventilation.....	47
III. Daily Management and Monitoring of ECMO (Extra Corporeal Membrane Oxygenation).....	49
IV. Nursing Care of ALSS (Artificial Liver Support System).....	50
V. Continuous Renal Replacement Treatment (CRRT) Care.....	51
VI. General Care.....	52

Appendix

I. Medical Advice Example for COVID-19 Patients.....	53
II. Online Consultation Process for Diagnosis and Treatment.....	57

References.....	59
-----------------	----

Part One Prevention and Control Management

I. Isolation Area Management

1 Fever Clinic

1.1 Layout

- (1) Healthcare facilities shall set up a relatively independent fever clinic including an exclusive one-way passage at the entrance of the hospital with a visible sign;
- (2) The movement of people shall follow the principle of “three zones and two passages” : a contaminated zone, a potentially contaminated zone and a clean zone provided and clearly demarcated, and two buffer zones between the contaminated zone and the potentially contaminated zone;
- (3) An independent passage shall be equipped for contaminated items; set up a visual region for one-way delivery of items from an office area (potentially contaminated zone) to an isolation ward (contaminated zone);
- (4) Appropriate procedures shall be standardized for medical personnel to put on and take off their protective equipment. Make flowcharts of different zones, provide full-length mirrors and observe the walking routes strictly;
- (5) Infection prevention and control technicians shall be assigned to supervise the medical personnel on putting on and removing protective equipment so as to prevent contamination;
- (6) All items in the contaminated zone that have not been disinfected shall not be removed.

1.2 Zone Arrangement

- (1) Set up an independent examination room, a laboratory, an observation room, and a resuscitation room;
- (2) Set up a pre-examination and triage area to perform preliminary screening of patients;
- (3) Separate diagnosis and treatment zones: those patients with an epidemiological history and fever and/or respiratory symptoms shall be guided into a suspected COVID-19 patient zone; those patients with regular fever but no clear epidemiological history shall be guided into a regular fever patient zone.

1.3 Patient Management

- (1) Patients with fevers must wear medical surgical masks;
- (2) Only patients are allowed to enter the waiting area in order to avoid overcrowding;
- (3) The duration of the patient's visit shall be minimized so as to avoid cross infections;
- (4) Educate patients and their families about early identification of symptoms and essential preventative actions.

1.4 Screening, Admission and Exclusion

- (1) All healthcare workers shall fully understand the epidemiological and clinical features of COVID-19 and screen patients in accordance with the screening criteria below (see Table 1);
- (2) Nucleic acid testing (NAT) shall be conducted on those patients who meet the screening criteria for suspected patients;
- (3) Patients who do not meet the screening criteria above, if they do not have a confirmed epidemiological history, but cannot be ruled out from having COVID-19 based on their symptoms, especially through imaging, are recommended for further evaluation and to obtain a comprehensive diagnosis;
- (4) Any patient who tests negative shall be re-tested 24 hours later. If a patient has two negative NAT results and negative clinical manifestations, then he or she can be ruled out from having COVID-19 and discharged from the hospital. If those patients cannot be ruled out from having COVID-19 infections based on their clinical manifestations, they shall be subjected to additional NAT tests every 24 hours until they are excluded or confirmed;
- (5) Those confirmed cases with a positive NAT result shall be admitted and treated collectively based on the severity of their conditions (the general isolation ward or isolated ICU).

Table 1 Screening Criteria for Suspected COVID-19 Cases

Epidemiological History	① Within 14 days before the onset of the disease, the patient has a travel or residence history in the high-risk regions or countries; ② Within 14 days before the onset of the disease, the patient has a history of contact with those infected with SARS-CoV-2 (those with a positive NAT result); ③ Within 14 days before the onset of the disease, the patient had direct contact with patients with fever or respiratory symptoms in high-risk regions or countries; ④ Disease clustering (2 or more cases with fever and/or respiratory symptoms occur at such places as homes, offices, school classrooms, etc. within 2 weeks).	The patient meets 1 epidemiological history and 2 clinical manifestations.	The patient has no epidemiological history and meets 3 clinical manifestations.	The patient has no epidemiological history, meets 1-2 clinical manifestations, but cannot be excluded from COVID-19 through imaging.
Clinical Manifestations	① The patient has fever and/or respiratory symptoms; ② The patient has the following CT imaging features of COVID-19: multiple patchy shadows and interstitial changes occur early, particularly at the lung periphery. The conditions further develop into multiple ground-glass opacities and infiltrates in both lungs. In severe cases, the patient may have lung consolidation and rare pleural effusion; ③ The white blood cells count in the early stage of the disease is normal or decreased, or the lymphocyte count decreases over time.			
Suspected Case Diagnosis		Yes	Yes	Expert consultation

II. Staff Management

1 Workflow Management

- (1) Before working in a fever clinic and isolation ward, the staff must undergo strict training and examinations to ensure that they know how to put on and remove personal protective equipment. They must pass such examinations before being allowed to work in these wards.
- (2) The staff should be divided into different teams. Each team should be limited to a maximum of 4 hours of working in an isolation ward. The teams shall work in the isolation wards (contaminated zones) at different times.
- (3) Arrange treatment, examination and disinfection for each team as a group to reduce the frequency of staff moving in and out of the isolation wards.
- (4) Before going off duty, staff must wash themselves and conduct necessary personal hygiene regimens to prevent possible infection of their respiratory tracts and mucosa.

2 Health Management

- (1) The front-line staff in the isolation areas – including healthcare personnel, medical technicians and property & logistics personnel – shall live in an isolation accommodation and shall not go out without permission.
- (2) A nutritious diet shall be provided to improve the immunity of medical personnel.
- (3) Monitor and record the health status of all staff on the job, and conduct health monitoring for front-line staff, including monitoring body temperature and respiratory symptoms; help address any psychological and physiological problems that arise with relevant experts.
- (4) If the staff have any relevant symptoms such as fever, they shall be isolated immediately and screened with an NAT.
- (5) When the front-line staff including healthcare personnel, medical technicians and property & logistics personnel finish their work in the isolation area and are returning to normal life, they shall first be NAT tested for SARS-CoV-2. If negative, they shall be isolated collectively at a specified area for 14 days before being discharged from medical observation.

III. COVID-19 Related Personal Protection Management


Protection Level	Protective Equipment	Scope of Application
Level I protection	• Disposable surgical cap • Disposable surgical mask • Work uniform • Disposable latex gloves or/and disposable isolation clothing if necessary	• Pre-examination triage, general outpatient department
Level II protection	• Disposable surgical cap • Medical protective mask (N95) • Work uniform • Disposable medical protective uniform • Disposable latex gloves • Goggles	• Fever outpatient department • Isolation ward area (including isolated intensive ICU) • Non-respiratory specimen examination of suspected/confirmed patients • Imaging examination of suspected/confirmed patients • Cleaning of surgical instruments used with suspected/confirmed patients
Level III protection	• Disposable surgical cap • Medical protective mask (N95) • Work uniform • Disposable medical protective uniform • Disposable latex gloves • Full-face respiratory protective devices or powered air-purifying respirator	• When the staff performs operations such as tracheal intubation, tracheotomy, bronchofibroscope, gastroenterological endoscope, etc., during which, the suspected/confirmed patients may spray or splash respiratory secretions or body fluids/blood • When the staff performs surgery and autopsy for confirmed/suspected patients • When the staff carries out NAT for COVID-19

Notes:

1. All staff at the healthcare facilities must wear medical surgical masks;
2. All staff working in the emergency department, outpatient department of infectious diseases, outpatient department of respiratory care, department of stomatology or endoscopic examination room (such as gastrointestinal endoscopy, bronchofibroscopy, laryngoscopy, etc.) must upgrade their surgical masks to medical protective masks (N95) based on Level I protection;
3. Staff must wear a protective face screen based on Level II protection while collecting respiratory specimens from suspected/confirmed patients.


IV. Hospital Practice Protocols during COVID-19 Epidemic

1 Guidance on Donning and Removing Personal Protective Equipment (PPE) to manage COVID-19 Patients



Protocol for Donning PPE:

Put on special work clothes and work shoes → Wash hands → Put on disposable surgical cap → Put on medical protective mask (N95) → Put on inner disposable nitrile/latex gloves → Put on goggles and protective clothing (note: if wearing protective clothing without foot covers, please also put on separate waterproof boot covers), put on a disposable isolation gown (if required in the specific work zone) and face shield/powered air-purifying respirator(if required in the specific work zone) → Put on outer disposable latex gloves



Protocol for Removing PPE:

Wash hands and remove visible bodily fluids/blood contaminants on the outer surfaces of both hands → Wash hands replace outer gloves with new gloves → Remove powered air-purifying respirator or self-priming filter-type full-face mask/mask (if used) → Wash hands → Remove disposable gowns along with outer gloves (if used) → Wash hands and put on outer gloves → Enter Removal Area No. ① → Wash hands and remove protective clothing along with outer gloves (for gloves and protective clothing, turn inside out, while rolling them down) (note: if used, remove the waterproof boot covers with clothing) → Wash hands → Enter Removal Area No. ② → Wash hands and remove goggles → Wash hands and remove mask → Wash hands and remove cap → Wash hands and remove inner disposable latex gloves → Wash hands and leave Removal Area No. ② → Wash hands, take a shower, put on clean clothes and enter the clean area

2 Disinfection Procedures for COVID-19 Isolation Ward Area

2.1 Disinfection for Floor and Walls

- (1) Visible pollutants shall be completely removed before disinfection and handled in accordance with disposal procedures of blood and bodily fluid spills;
- (2) Disinfect the floor and walls with 1000 mg/L chlorine-containing disinfectant through floor mopping, spraying or wiping;
- (3) Make sure that disinfection is conducted for at least 30 minutes;
- (4) Carry out disinfection three times a day and repeat the procedure at any time when there is contamination.

2.2 Disinfection of Object Surfaces

- (1) Visible pollutants should be completely removed before disinfection and handled in accordance with disposal procedures of blood and bodily fluid spills;
- (2) Wipe the surfaces of objects with 1000 mg/L chlorine-containing disinfectant or wipes with effective chlorine; wait for 30 minutes and then rinse with clean water. Perform disinfection procedure three times a day (repeat at any time when contamination is suspected);
- (3) Wipe cleaner regions first, then more contaminated regions: first wipe the object surfaces that are not frequently touched, and then wipe the object surfaces that are frequently touched. (Once an object surface is wiped clean, replace the used wipe with a new one).

2.3 Air Disinfection

- (1) Plasma air sterilizers can be used and continuously run for air disinfection in an environment with human activity;
- (2) If there is no plasma air sterilizers, use ultraviolet lamps for 1 hour each time. Perform this operation three times a day.

2.4 Disposal of Fecal Matter and Sewage

- (1) Before being discharged into the municipal drainage system, fecal matter and sewage must be disinfected by treating with chlorine-containing disinfectant (for the initial treatment, the active chlorine must be more than 40 mg/L). Make sure the disinfection time is at least 1.5 hours;
- (2) The concentration of total residual chlorine in the disinfected sewage should reach 10 mg/L.

3 Disposal Procedures for Spills of COVID-19 Patient Blood/Fluids

3.1 For spills of a small volume (< 10 mL) of blood/bodily fluids:

(1) Option 1: The spills should be covered with chlorine-containing disinfecting wipes (containing 5000 mg/L effective chlorine) and carefully removed, then the surfaces of the object should be wiped twice with chlorine-containing disinfecting wipes (containing 500 mg/L effective chlorine);

(2) Option 2: Carefully remove the spills with disposable absorbent materials such as gauze, wipes, etc., which have been soaked in 5000 mg/L chlorine-containing disinfecting solution.

3.2 For spills of a large volume (> 10 mL) of blood and bodily fluids:

(1) First, place signs to indicate the presence of a spill;

(2) Perform disposal procedures according to Option 1 or 2 described below:

① Option 1: Absorb the spilled fluids for 30 minutes with a clean absorbent towel (containing peroxyacetic acid that can absorb up to 1 L of liquid per towel) and then clean the contaminated area after removing the pollutants.

② Option 2: Completely cover the spill with disinfectant powder or bleach powder containing water-absorbing ingredients or completely cover it with disposable water-absorbing materials and then pour a sufficient amount of 10,000 mg/L chlorine-containing disinfectant onto the water-absorbing material (or cover with a dry towel which will be subjected to high-level disinfection). Leave for at least 30 minutes before carefully removing the spill.

(3) Fecal matter, secretions, vomit, etc. from patients shall be collected into special containers and disinfected for 2 hours by a 20,000 mg/L chlorine-containing disinfectant at a spill-to-disinfectant ratio of 1:2.

(4) After removing the spills, disinfect the surfaces of the polluted environment or objects.


(5) The containers that hold the contaminants can be soaked and disinfected with 5,000 mg/L active chlorine-containing disinfectant for 30 minutes and then cleaned.

(6) The collected pollutants should be disposed of as medical waste.

(7) The used items should be put into double-layer medical waste bags and disposed of as medical waste.

4 Disinfection of COVID-19 Related Reusable Medical Devices

4.1 Disinfection of powered air-purifying respirator



Note: The disinfection procedures for protective hood described above are only for reusable protective hoods (excluding disposable protective hoods).

4.2 Cleaning and Disinfection Procedures for Digestive Endoscopy and Bronchofibroscopy

- (1) Soak the endoscope and reusable valves in 0.23% peroxyacetic acid (confirm the concentration of the disinfectant before use to make sure it will be effective);
- (2) Connect the perfusion line of each channel of the endoscope, inject 0.23% peroxyacetic acid liquid into the line with a 50 mL syringe until fully filled, and wait for 5 minutes;
- (3) Detach the perfusion line and wash each cavity and valve of the endoscope with a disposable special cleaning brush;
- (4) Put the valves into an ultrasonic oscillator containing enzyme to oscillate it. Connect the perfusion line of each channel with the endoscope. Inject 0.23% peroxyacetic acid into the line with a 50 mL syringe and flush the line continuously for 5 minutes. Inject air to dry it for 1 minute;
- (5) Inject clean water into the line with a 50 mL syringe and flush the line continuously for 3 minutes. Inject air to dry it for 1 minute;
- (6) Perform a leakage test on the endoscope;
- (7) Put in an automatic endoscopic washing and disinfection machine. Set a high level of disinfection for treatment;
- (8) Send the devices to the disinfection supply center to undergo sterilization with ethylene oxide.


4.3 Pre-treatment of Other Reusable Medical Devices

- (1) If there are no visible pollutants, soak the device in 1000 mg/L chlorine-containing disinfectant for at least 30 minutes;
- (2) If there are any visible pollutants, soak the device in 5000 mg/L chlorine-containing disinfectant for at least 30 minutes;
- (3) After drying, pack and fully enclose the devices and send them to the disinfection supply center.

6 Disposal Procedures for COVID-19 Related Medical Waste

- (1) All waste generated from suspected or confirmed patients shall be disposed of as medical waste;
- (2) Put the medical waste into a double-layer medical waste bag, seal the bag with cable ties in a gooseneck fashion and spray the bag with 1000 mg/L chlorine-containing disinfectant;
- (3) Put sharp objects into a special plastic box, seal the box and spray the box with 1000 mg/L chlorine-containing disinfectant;
- (4) Put the bagged waste into a medical waste transfer box, attach a special infection label, fully enclose the box and transfer it;
- (5) Transfer the waste to a temporary storage point for medical waste along a specified route at a fixed time point and store the waste separately at a fixed location;
- (6) The medical waste shall be collected and disposed of by an approved medical waste disposal provider.

7 Procedures for Taking Remedial Actions against Occupational Exposure to COVID-19



- (1) Skin exposure: The skin is directly contaminated by a large amount of visible bodily fluids, blood, secretions or fecal matter from the patient.
- (2) Mucous membrane exposure: Mucous membranes, such as the eyes and respiratory tract are directly contaminated by visible bodily fluids, blood, secretions or fecal matter from the patient.
- (3) Sharp object injury: Piercing of the body by sharp objects that were directly exposed to the patient's bodily fluids, blood, secretions or fecal matter.
- (4) Direct exposure of respiratory tract: Falling off of a mask, exposing the mouth or nose to a confirmed patient (1 meter away) who is not wearing a mask.

8 Surgical Operations for Suspected or Confirmed Patients

8.1 Requirements for Operation Rooms and Staff PPE

- (1) Arrange the patient in a negative pressure operating room. Verify the temperature, humidity and air pressure in the operation room;
- (2) Prepare all required items for the operation and use disposable surgical items if possible;
- (3) All surgical personnel (including surgeons, anesthesiologists, hand-washing nurses, and charge nurses in operating room) should put on their PPE in the buffer room before entering the operating room: Put on double caps, medical protective mask (N95), medical goggles, medical protective clothing, boot covers, latex gloves, and powered air-purifying respirator;
- (4) The surgeons and the hand-washing nurses should wear disposable sterile operating clothes and sterile gloves in addition to the PPE as mentioned above;
- (5) Patients should wear disposable caps and disposable surgical masks according to their situation;
- (7) The charge nurses in the buffer room are responsible for delivering items from the buffer area to the negative pressure operating room;
- (8) During the operation, the buffer room and the operating room shall be tightly closed, and the operation must be carried out only if the operation room is under negative pressure;
- (9) Irrelevant personnel shall be excluded from entering the operating room.

8.2 Procedures for Final Disinfection

- (1) Medical waste shall be disposed of as COVID-19 related medical waste;
- (2) Reusable medical devices shall be disinfected according to the disinfection procedures of SARS-CoV-2 related reusable medical devices;
- (3) Medical fabrics shall be disinfected and disposed of according to the disinfection procedures for SARS-CoV-2 related infectious fabrics;
- (4) Surfaces of objects (instruments and devices including device table, operating table, operating bed, etc.);
 - ① Visible blood/bodily fluid pollutants shall be completely removed before disinfection (handled in accordance with disposal procedures of blood and bodily fluid spills).
 - ② All surfaces shall be wiped with a disinfectant containing 1000 mg/L active chlorine and allowed to sit for 30 minutes with the disinfectant.
- (5) Floors and walls:
 - ① Visible blood/bodily fluid pollutants shall be completely removed before disinfection (handled in accordance with disposal procedures of blood and bodily fluid spills).
 - ② All surfaces shall be wiped with a disinfectant containing 1000 mg/L active chlorine and allowed to sit for 30 minutes with the disinfectant.
- (6) Indoor air: Turn off the fan filter unit (FFU). Disinfect the air by irradiation by ultraviolet lamp for at least 1 hour. Turn on the FFU to purify the air automatically for at least 2 hours.

9 Procedures for Handling Bodies of Deceased Suspected or Confirmed Patients

- (1) Staff PPE: The staff must make sure they are fully protected by wearing work clothes, disposable surgical caps, disposable gloves and thick rubber gloves with long sleeves, medical disposable protective clothing, medical protective masks (N95) or powered air purifying respirators (PAPRs), protective face shields, work shoes or rubber boots, waterproof boot covers, waterproof aprons or waterproof isolation gowns, etc.
- (2) Corpse care: Fill all openings or wounds the patient may have, such as mouth, nose, ears, anus and tracheotomy openings, by using cotton balls or gauze dipped in 3000-5000 mg/L chlorine-containing disinfectant or 0.5% peroxyacetic acid.
- (3) Wrapping: Wrap the corpse with a double-layer cloth sheet soaked with disinfectant, and pack it into a double-layer, sealed, leak-proof corpse wrapping sheet soaked with chlorine containing disinfectant.
- (4) The body shall be transferred by the staff in the isolation ward of the hospital via the contaminated area to the special elevator, out of the ward and then directly transported to a specified location for cremation by a special vehicle as soon as possible.
- (5) Final disinfection: Perform final disinfection of the ward and the elevator.

[FAHZU Internert + Hospital - A Model for Online Healthcare]

Since the outbreak of COVID 19, FAHZU Internet+ Hospital quickly shifted to offer online healthcare through Zhejiang's Online Medical Platform with 24-hour free online consultation, providing telemedicine service to patients in China and even around the world. Patients are provided access to the first-rate medical services of FAHZU at home, which reduces the chances of transmission and cross infection as a result of their visits to the hospital. As of March 14, over 10,000 people have used the FAHZU Internet+ Hospital online service.

• Instructions for Zhejiang Online Medical Platform:

- ① Download Alipay app;
- ② Open Alipay (China Version) and find "Zhejiang Provincial Online Medical Platform" ;
- ③ Choose a hospital (The First Affiliated Hospital, Zhejiang University School of Medicine);
- ④ Post your question and wait for a doctor to respond;
- ⑤ A notification will pop up when a doctor replies. Then open Alipay and click Friends;
- ⑥ Click Zhejiang Online Medical Platform to see more details and start your consultation.

[Establishing the International Medical Expert Communication Platform of the First Affiliated Hospital, Zhejiang University School of Medicine]

Due to the spread of the COVID-19 epidemic, the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) and Alibaba jointly established the International Medical Expert Communication Platform of FAHZU with an aim to improve the quality of care and treatment and promote the sharing of global information resource. The platform allows medical experts all over the world to connect and share their invaluable experience in the fight against COVID-19 through instant messaging with real-time translation, remote video conferencing, etc.

• Instructions on the International Medical Expert Communication Platform of The First Affiliated Hospital, Zhejiang University School of Medicine

- ① Visit www.dingtalk.com/en to download DingTalk app.
- ② Sign up with your personal information (Name and Phone Number) and log in.
- ③ Apply to join the International Medical Expert Communication Platform of FAHZU:
 Method 1: Join by team code. Select "Contacts" > "Join Team" > "Join by Team Code", then enter the Input ID: 'YQDK1170'.
 Method 2: Join by scanning the QR code of the International Medical Expert Communication Platform of FAHZU.
- ④ Fill out your information to join. Enter your name, country and medical institution.
- ⑤ Join the FAHZU group chat after the admin has approved.
- ⑥ After joining the group chat, medical staff can send instant messages assisted by AI translation, receive remote video guidance, and access to medical treatment guidelines.



I. Personalized, Collaborative and Multidisciplinary Management

FAHZU is a designated hospital for COVID-19 patients, especially severe and critically ill individuals whose condition changes rapidly, often with multiple organs infected and requiring the support from the multidisciplinary team (MDT). Since the outbreak, FAHZU established an expert team composed of doctors from the Departments of Infectious Diseases, Respiratory Medicine, ICU, Laboratory Medicine, Radiology, Ultrasound, Pharmacy, Traditional Chinese Medicine, Psychology, Respiratory Therapy, Rehabilitation, Nutrition, Nursing, etc. A comprehensive multidisciplinary diagnosis and treatment mechanism has been established in which doctors both inside and outside the isolation wards can discuss patients' conditions every day via video conference. This allows for them to determine scientific, integrated and customized treatment strategies for every severe and critically ill patient.

Sound decision-making is the key to MDT discussion. During the discussion, experts from different departments focus on issues from their specialized fields as well as critical issues to diagnoses and treatment. The final treatment solution is determined by experienced experts through various discussions of different opinions and advice.

Systematic analysis is at the core of MDT discussion. Elderly patients with underlying health conditions are prone to becoming critically ill. While closely monitoring the progression of COVID-19, the patient's basic status, complications and daily examination results should be analyzed comprehensively to see how the disease will progress. It is necessary to intervene in advance to stop the disease from deteriorating and to take proactive measures such as antivirals, oxygen therapy, and nutritional support.

The goal of MDT discussion is to achieve personalized treatment. The treatment plan should be adjusted to each person when considering the differences among individuals, courses of disease, and patient types.

Our experience is that MDT collaboration can greatly improve the effectiveness of the diagnosis and treatment of COVID-19.

II. Etiology and Inflammation Indicators

1 Detection of SARS-CoV-2 Nucleic Acid

1.1 Specimen Collection

Appropriate specimens, collection methods and collection timing are important to improve detection sensitivity. Specimen types include: upper airway specimens (pharyngeal swabs, nasal swabs, nasopharyngeal secretions), lower airway specimens (sputum, airway secretions, bronchoalveolar lavage fluid), blood, feces, urine and conjunctival secretions. Sputum and other lower respiratory tract specimens have a high positive rate of nucleic acids and should be collected preferentially. SARS-CoV-2 preferentially proliferates in type II alveolar cells (AT2) and peak of viral shedding appears 3 to 5 days after the onset of disease. Therefore, if the nucleic acid test is negative at the beginning, samples should continue to be collected and tested on subsequent days.

1.2 Nucleic Acid Detection

Nucleic acid testing is the preferred method for diagnosing SARS-CoV-2 infection. The testing process according to the kit instructions is as follows: Specimens are pre-processed, and the virus is lysed to extract nucleic acids. The three specific genes of SARS-CoV-2, namely the Open Reading Frame 1a/b (ORF1a/b), nucleocapsid protein (N), and envelope protein (E) genes, are then amplified by real-time quantitative PCR technology. The amplified genes are detected by fluorescence intensity. Criteria of positive nucleic acid results are: ORF1a/b gene is positive, and/or N gene/E gene are positive.

The combined detection of nucleic acids from multiple types of specimens can improve the diagnostic accuracy. Among patients with confirmed positive nucleic acid in respiratory tract, about 30% - 40% of these patients have detected viral nucleic acid in the blood and about 50% - 60% of patients have detected viral nucleic acid in feces. However, the positive rate of nucleic acid testing in urine samples is quite low. Combined testing with specimens from respiratory tract, feces, blood and other types of specimens is helpful for improving the diagnostic sensitivity of suspected cases, monitoring treatment efficacy and the management of post-discharge isolation measures.

2 Virus Isolation and Culture

Virus culture must be performed in a laboratory with qualified Biosafety Level 3 (BSL-3). The process is briefly described as follows: Fresh samples of the patient's sputum, feces, etc. are obtained and inoculated on Vero-E6 cells for virus culture. The cytopathic effect (CPE) is observed after 96 hours. Detection of viral nucleic acid in the culture medium indicates a successful culture. Virus titer measurement: After diluting the virus stock concentration by a factor of 10 in series, the TCID₅₀ is determined by the micro-cytopathic method. Otherwise, viral viability is determined by plaque forming unit (PFU).

3 Detection of Serum Antibody

Specific antibodies are produced after SARS-CoV-2 infection. Serum antibody determination methods include colloidal gold immunochromatography, ELISA, chemiluminescence immunoassay, etc. Positive serum-specific IgM, or specific IgG antibody titer in the recovery phase ≥ 4 times higher than that in the acute phase, can be used as diagnostic criteria for suspected patients with negative nucleic acid detection. During follow-up monitoring, IgM is detectable 10 days after symptom onset and IgG is detectable 12 days after symptom onset. The viral load gradually decreases with the increase of serum antibody levels.

4 Detecting Indicators of Inflammatory Response

It is recommended to conduct tests of C-reactive protein, procalcitonin, ferritin, D-dimer, total and subpopulations of lymphocytes, IL-4, IL-6, IL-10, TNF- α , INF- γ and other indicators of inflammation and immune status, which can help evaluate clinical progress, alert severe and critical tendencies, and provide a basis for the formulation of treatment strategies.

Most patients with COVID-19 have a normal level of procalcitonin with significantly increased levels of C-reactive protein. A rapid and significantly elevated C-reactive protein level indicates a possibility of secondary infection. D-dimer levels are significantly elevated in severe cases, which is a potential risk factor for poor prognosis. Patients with a low total number of lymphocytes at the beginning of the disease generally have a poor prognosis. Severe patients have a progressively decreased number of peripheral blood lymphocytes. The expression levels of IL-6 and IL-10 in severe patients are increased greatly. Monitoring the levels of IL-6 and IL-10 is helpful to assess the risk of progression to a severe condition.

5 Detection of Secondary Bacterial or Fungal Infections

Severe and critically ill patients are vulnerable to secondary bacterial or fungal infections. Qualified specimens should be collected from the infection site for bacterial or fungal culture. If secondary lung infection is suspected, sputum coughed from deep in the lungs, tracheal aspirates, bronchoalveolar lavage fluid, and brush specimens should be collected for culture. Timely blood culture should be performed in patients with high fever. Blood cultures drawn from peripheral venous or catheters should be performed in patients with suspected sepsis who had an indwelling catheter. It is recommended that they take blood G test and GM test at least twice a week in addition to fungal culture.


6 Laboratory Safety

Biosafety protective measures should be determined based on different risk levels of experimental process. Personal protection should be taken in accordance with BSL-3 laboratory protection requirements for respiratory tract specimen collection, nucleic acid detection and virus culture operations. Personal protection in accordance with BSL-2 laboratory protection requirement should be carried out for biochemical, immunological tests and other routine laboratory tests. Specimens should be transported in special transport tanks and boxes that meet biosafety requirements. All laboratory waste should be strictly autoclaved.

III. Imaging Findings of COVID-19 Patients

Thoracic imaging is of great value in the diagnosis of COVID-19, monitoring of therapeutic efficacy, and patient discharge assessment. A high-resolution CT is highly preferable. Portable chest X-rays are helpful for critically ill patients who are immobile. CT for baseline evaluation of patients with COVID-19 is usually performed on the day of admission, or if ideal therapeutic efficacy is not reached, it can be re-performed after 2 to 3 days. If symptoms are stable or improved after treatment, the chest CT scan can be reviewed after 5 to 7 days. Daily routine portable chest X-rays are recommended for critically ill patients.

COVID-19 at the early stage often presents with multifocal patchy shadows or ground glass opacities located in the lung periphery, subpleural area, and both lower lobes on chest CT scans. The long axis of the lesion is mostly parallel to the pleura. Interlobular septal thickening and intralobular interstitial thickening, displaying as subpleural reticulation namely a "crazy paving" pattern, is observed in some ground glass opacities. A small number of cases may show solitary, local lesions, or nodular/ patchy lesion distributed consistent with bronchus with peripheral ground glass opacities changes. Disease progression mostly occurs in the course of 7-10 days, with enlarged and increased density of the lesions compared with previous images, and consolidated lesions with air bronchogram sign. Critical cases may show further expanded consolidation, with the whole lung density showing increased opacity, sometimes known as a "white lung". After the condition is relieved, the ground glass opacities can be completely absorbed, and some consolidation lesions will leave fibrotic stripes or subpleural reticulation. Patients with multiple lobular involvement, especially those with expanded lesions should be observed for disease exacerbation. Those with typical CT pulmonary manifestations should be isolated and undergo continuous nucleic acid tests even if the nucleic acid test of SAR-CoV-2 is negative.



Typical CT features of COVID-19 :

Figure 1, Figure 2: patchy ground glass opacities;

Figure 3: nodules and patchy exudation;

Figure 4, Figure 5: multifocal consolidation lesions;

Figure 6: diffuse consolidation, "white lung".

IV. Application of Bronchoscopy in the Diagnosis and Management of COVID-19 Patients

Flexible bronchoscopy is versatile, easy to use, and well tolerated in mechanically ventilated COVID-19 patients. Its applications include:

(1) Collection of respiratory specimens from the lower respiratory tract (i.e. sputum, endotracheal aspirate, bronchoalveolar lavage) for SARS-CoV-2 or other pathogens guides the selection of appropriate antimicrobials, which may lead to clinical benefits. Our experience indicates that lower respiratory specimens are more likely to be positive for SARS-CoV-2 than upper respiratory specimens.

(2) Can be used for localization of the site of bleeding, cessation of hemoptysis, sputum or blood clots removal; if the site of bleeding is identified by bronchoscopy, local injection of cold saline, epinephrine, vasopressin, or fibrin as well as laser treatment can be performed via the bronchoscope.

(3) Assist in the establishment of artificial airways; guide tracheal intubation or percutaneous tracheotomy.

(4) Drugs such as infusion of α -interferon and N-acetylcysteine can be administered via the bronchoscope.

Bronchoscopic views of extensive bronchial mucosal hyperemia, swelling, mucus-like secretions in the lumen and jelly-like sputum blocking the airway in critically ill patients. (Figure 7).



Figure 7: Bronchoscopic manifestations of COVID-19: bronchial mucosa swelling and congestion; large amounts of mucus secretions in the lumen

V. Diagnosis and Clinical Classification of COVID-19

Early diagnosis, treatment and isolation should be carried out whenever possible. Dynamic monitoring of lung imaging, oxygenation index and cytokine levels are helpful for early identification of patients who may develop into severe and critical cases. A positive result of the nucleic acid of SARS-CoV-2 is the gold standard for the diagnosis of COVID-19. However, considering the possibility of false negatives in nucleic acid detection, suspected cases characteristic manifestations in CT scans can be treated as confirmed cases even if the nucleic acid test is negative. Isolation and continuous tests of multiple specimens should be carried out in such cases.

The diagnostic criteria follow Protocols for the Diagnosis and Treatment of COVID-2019. A confirmed case is based on epidemiological history (including cluster transmission), clinical manifestations (fever and respiratory symptoms), lung imaging, and results of SARS-CoV-2 nucleic acid detection and serum-specific antibodies.

Clinical Classifications:

1 Mild Cases

The clinical symptoms are mild and no pneumonia manifestations can be found in imaging.

2 Moderate Cases

Patients have symptoms such as fever and respiratory tract symptoms, etc. and pneumonia manifestations can be seen in imaging.

3 Severe Cases

Adults who meet any of the following criteria: respiratory rate ≥ 30 breaths/min; oxygen saturation $\leq 93\%$ at a rest state; arterial partial pressure of oxygen (PaO_2)/oxygen concentration (FiO_2) ≤ 300 mmHg. Patients with $> 50\%$ lesions progression within 24 to 48 hours in lung imaging should be treated as severe cases.

4 Critical Cases

Meeting any of the following criteria: occurrence of respiratory failure requiring mechanical ventilation; presence of shock; other organ failure that requires monitoring and treatment in the ICU.

Critical cases are further divided into early, middle and late stages according to the oxygenation index and compliance of respiratory system.

- **Early stage:** $100 \text{ mmHg} < \text{oxygenation index} \leq 150 \text{ mmHg}$; compliance of respiratory system $\geq 30 \text{ mL} / \text{cmH}_2\text{O}$; without organ failure other than the lungs. The patient has a great chance of recovery through active antiviral, anti-cytokine storm, and supportive treatment.

- **Middle stage:** $60 \text{ mmHg} < \text{oxygenation index} \leq 100 \text{ mmHg}$; $30 \text{ mL/cmH}_2\text{O} > \text{compliance of respiratory system} \geq 15 \text{ mL/cmH}_2\text{O}$; may be complicated by other mild or moderate dysfunction of other organs.

- **Late stage:** $\text{oxygenation index} \leq 60 \text{ mmHg}$; compliance of respiratory system $< 15 \text{ mL/cmH}_2\text{O}$; diffuse consolidation of both lungs that requires the use of ECMO; or failure of other vital organs. The mortality risk is significantly increased.

VI. Antiviral Treatment for Timely Elimination of Pathogens

An early antiviral treatment can reduce the incidence of severe and critical cases. Although there is no clinical evidence for effective antiviral drugs, currently the antiviral strategies based on the characteristics of SAR-CoV-2 are adopted according to Protocols for Diagnosis and Treatment of COVID-19: Prevention, Control, Diagnosis and Management.

1 Antiviral Treatment

At FAHZU, lopinavir/ritonavir (2 capsules, po q12h) combined with arbidol (200 mg po q12h) were applied as the basic regimen. From the treatment experience of 49 patients in our hospital, the average time to achieve negative viral nucleic acid test for the first time was 12 days (95% CI: 8-15 days). The duration of negative nucleic acid test result (negative for more than 2 times consecutively with interval ≥ 24 h) was 13.5 days (95% CI: 9.5 - 17.5 days).

If the basic regimen is not effective, chloroquine phosphate can be used on adults between 18-65 years old (weight ≥ 50 kg: 500 mg bid; weight ≤ 50 kg: 500 mg bid for first two days, 500 mg qd for following five days).

Interferon nebulization is recommended in Protocols for Diagnosis and Treatment of COVID-19. We recommend that it should be performed in negative-pressure wards rather than general wards due to the possibility of aerosol transmission.

Darunavir/cobicistat has some degree of antiviral activity in viral suppression test in vitro, based on the treatment experience of AIDS patients, and the adverse events are relatively mild. For patients who are intolerant to lopinavir/ritonavir, darunavir/ cobicistat (1 tablet qd) or favipiravir (starting dose of 1600 mg followed by 600 mg tid) is an alternative option after the ethical review. Simultaneous use of three or more antiviral drugs is not recommended.

2 Course of Treatment

The treatment course of chloroquine phosphate should be no more than 7 days. The treatment course of other regimens has not been determined and are usually around 2 weeks. Antiviral drugs should be stopped if nucleic acid test results from sputum specimens remain negative for more than 3 times.

VII. Anti-shock and Anti-hypoxemia Treatment

During the progression from the severe to critically ill stage, patients may develop severe hypoxemia, cytokine cascade and severe infections that might develop into shock, tissue perfusion disorders, and even multiple organ failure. Treatment is aimed at incentive removal and fluid recovery. The artificial liver support system (ALSS) and blood purification can effectively diminish inflammatory mediators and cytokine cascade and prevent the incidence of shock, hypoxemia and respiratory distress syndrome.

1 Usage of Glucocorticoids when Necessary

Appropriate and short-term use of corticosteroids to inhibit cytokine cascade and to prevent disease progression should be considered for patients with severe COVID-19 pneumonia as early as possible. However, a high dose of glucocorticoids should be avoided due to adverse events and complications.

1.1 Indication for Corticosteroids

- ① for those in severe and critically ill stage;
- ② for those with persistent high fever (temperature above 39°C);

2.2 Contraindications

There is no absolute contraindication in the treatment of critically ill patients. However, ALSS should be avoided in the following situations:

- ① Severe bleeding disease or disseminated intravascular coagulation;
- ② Those who are highly allergic to blood components or drugs used in the treatment process such as plasma, heparin and protamine;
- ③ Acute cerebrovascular diseases or severe head injury;
- ④ Chronic cardiac failure, cardiac functional classification $\geq$ grade III;
- ⑤ Uncontrolled hypotension and shock;
- ⑥ Severe arrhythmia.

Plasma exchange combined with plasma adsorption or dual plasma molecular adsorption, perfusion, and filtration is recommended according to the patients' situation. 2000 mL of plasma should be exchanged when ALSS is performed. Detailed operating procedures can be found in the Expert Consensus on the Application of Artificial Liver Blood Purification System in the Treatment of Severe and Critical Novel Coronavirus Pneumonia.

ALSS significantly reduces the time that critically ill patients stay in the ICU in our hospital. Typically, the levels of serum cytokines such as IL-2/IL-4/IL-6/TNF- α are remarkably decreased, and oxygen saturation is significantly improved after ALSS.

3 Oxygen Therapy for Hypoxemia

Hypoxemia can present due to impaired respiratory functions by COVID-19. Oxygen supplementation treatment can correct hypoxemia, relieving secondary organ damage caused by respiratory distress and hypoxemia.

3.1 Oxygen therapy

(1) Continual oxygen saturation monitoring during oxygen therapy

Some patients do not necessarily have impaired oxygenation functions at the onset of infection but may manifest rapid deterioration in oxygenation over time. Therefore, continual monitoring of oxygen saturation is recommended, before and during oxygen therapy.

(2) Oxygen therapy as soon as possible

Oxygen therapy is not necessary for patients with oxygen saturation (SpO_2) of more than 93% or for patients without obvious symptoms of respiratory distress without oxygen treatment. Oxygen therapy is strongly recommended to the patients with symptoms of respiratory distress. It should be noted that some severe patients with $\text{PaO}_2/\text{FiO}_2 < 300$ had no obvious symptoms of respiratory distress.

(3) Treatment goal of oxygen therapy

The treatment goal of oxygen therapy is to maintain the oxygen saturation (SpO_2) at 93%-96% for patients without chronic pulmonary disease and at 88%-92% for patients with chronic type II respiratory failure. Specially, the oxygen concentration should be increased to 92%-95% for patients whose SpO_2 drops below 85% frequently during daily activities.

(4) Control oxygen therapy

$\text{PaO}_2/\text{FiO}_2$ is a sensitive and accurate indicator of oxygenation function. The stability and monitorability of FiO_2 are very important for patients with disease progression and $\text{PaO}_2/\text{FiO}_2$ below 300 mmHg. Controlled oxygen therapy is the preferred treatment.

High-flow nasal cannula (HFNC) oxygen therapy is recommended for patients with the following conditions: $\text{SpO}_2 < 93\%$; $\text{PaO}_2/\text{FiO}_2 < 300$ mmHg (1 mmHg = 0.133 kPa); respiratory rate > 25 times per min at bed; or remarkable progression on X-ray imaging. Patients should wear a surgical mask during HFNC treatment. The airflow of HFNC oxygen therapy should start at a low level and gradually increased up to 40-60 L/min when $\text{PaO}_2/\text{FiO}_2$ is between 200-300 mmHg so that patients do not feel obvious chest tightness and shortness of breath. An initial flow of at least 60 L/min should be given immediately for patients with obvious respiratory distress.

Tracheal intubation for patients is dependent on disease progression, systemic status and complication of patients for those with stable situation but with a low oxygenation index (< 100 mmHg). Thus, detailed evaluations of the clinical condition of patients is very important before decision making. Tracheal intubation should be performed as early as possible for patients with an oxygenation index less than 150 mmHg, worsening symptoms of respiratory distress or multiple organ dysfunction within 1-2 hours after high-flow (60 L/min) and high-concentration ($> 60\%$) HFNC oxygen therapy.

Older patients (> 60 years old) with more complications or $\text{PaO}_2/\text{FiO}_2$ less than 200 mmHg should be treated in ICU.

3.2 Mechanical Ventilation

(1) Noninvasive Ventilation (NIV)

NIV is not strongly recommended in COVID-19 patients who fail HFNC treatment. Some severe patients progress to ARDS rapidly. Excessive inflation pressure may cause gastric distension and intolerance which contribute to aspiration and worsen lung injury. A short-term (less than 2 hours) use of NIV can be closely monitored if the patient has acute left heart failure, chronic obstructive pulmonary disease or is immunocompromised. Intubation should be performed as early as possible if improvement of respiratory distress symptoms or $\text{PaO}_2/\text{FiO}_2$ is not observed.

NIV with a double circuit is recommended. A virus filter should be installed between the mask and the exhalation valve when applying NIV with a single tube. Suitable masks should be chosen to reduce the risk of virus spread through air leakage.

(2) Invasive Mechanical Ventilation

① Principles of invasive mechanical ventilation in critically ill patients

It is important to balance the ventilation and oxygenation demands and the risk of mechanical ventilation-related lung injury in the treatment of COVID-19.

- Strictly set the tidal volume to 4 - 8 mL/kg. In general, the lower the lung compliance, the smaller the preset tidal volume should be.
- Maintain the platform pressure < 30 cmH₂O (1 cmH₂O = 0.098 kPa) and driving pressure < 15 cmH₂O.
- Set PEEP according to the ARDS's protocol.
- Ventilation frequency: 18-25 times per minute. Moderate hypercapnia is allowed.
- Administer sedation, analgesia, or muscle relaxant if the tidal volume, platform pressure and driving pressure are too high.

② Lung Recruitment

Lung recruitment improves the heterogeneous distribution of lesions in patients with ARDS. However, it may result in severe respiratory and circulatory complications and therefore, the lung recruitment maneuver is not routinely recommended. The assessment of lung expandability should be performed prior to the application.

(3) Prone Position Ventilation

Most critically ill patients with COVID-19 respond well to prone ventilation, with a rapid improvement of oxygenation and lung mechanics. Prone ventilation is recommended as a routine strategy for patients with $\text{PaO}_2/\text{FiO}_2 < 150$ mmHg or with obvious imaging manifestations without contraindications. Time course recommended for prone ventilation is more than 16 hours each time. The prone ventilation can be ceased once $\text{PaO}_2/\text{FiO}_2$ is greater than 150 mmHg for more than 4 hours in the supine position.

Prone ventilation while awake may be attempted for patients who have not been intubated or have no obvious respiratory distress but with impaired oxygenation or have consolidation in gravity-dependent lung zones on lung images. Procedures for at least 4 hours each time is recommended. Prone position can be considered several times per day depending on the effects and tolerance.

(4) Prevention of Regurgitation and Aspiration

Gastric residual volume and gastrointestinal function should be routinely evaluated. Appropriate enteral nutrition is recommended to be given as earlier as possible. Nasointestinal feeding and continuous nasogastric decompression are recommended. Enteral nutrition should be suspended and aspiration with 50 mL syringe be done before transfer. If no contraindication exists, a 30° semi-sitting position is recommended.

(5) Fluid Management

Excessive fluid burden worsens hypoxemia in COVID-19 patients. To reduce pulmonary exudation and improve oxygenation, the amount of fluid should be strictly controlled while ensuring the patient's perfusion.

(6) Strategies to Prevent Ventilator-Associated Pneumonia (VAP)

VAP bundled strategies should be strictly implemented:

- ① Select appropriate type of endotracheal tube;
- ② Use a endotracheal tube with subglottic suction (once every 2 hours, aspirated with 20 mL empty syringe each time);
- ③ Place the endotracheal tube at the right position and correct depth, fix properly and avoid pulling;

- ④ Maintain the airbag pressure at 30 - 35 cmH₂O (1 cmH₂O = 0.098 kPa) and monitor every 4 hours;
- ⑤ Monitor the airbag pressure and deal with water condensates when the position changes (two people cooperate in dumping and pouring the water condensates into a capped container containing a pre-made disinfectant chlorine solution); deal with secretions accumulated in the airbag;
- ⑥ Clean up secretions from the mouth and nose timely.

(7) Weaning of Ventilation

Sedatives is reduced and discontinued before awakening when the patient's PaO₂/FiO₂ is more than 150 mmHg. Intubation withdrawal should be performed as earlier as possible if permitted. HFNC or NIV is used for sequential respiratory support after withdrawal.



VIII. The Rational Use of Antibiotics to Prevent Secondary Infection

COVID-19 is a disease of viral infection, therefore antibiotics are not recommended to prevent bacterial infection in mild or ordinary patients; it should be used carefully in severe patients based on their conditions. Antibiotics can be used with discretion in patients who have the following conditions: extensive lung lesions; excess bronchial secretions; chronic airway diseases with a history of pathogen colonization in the lower respiratory tract; taking glucocorticoids with a dosage $\geq 20 \text{ mg} \times 7\text{d}$ (in terms of prednisone). The options of antibiotics

include quinolones, the second or third generation cephalothins, β -lactamase inhibitor compounds, etc. The antibiotics should be used for the prevention of bacterial infection in critically severe patients, especially those with invasive mechanical ventilation. The antibiotics such as carbapenems, β -lactamase inhibitor compounds, linezolid and vancomycin can be used in critically ill patients according to the individual risk factors.

The patient's symptoms, signs and indicators such as blood routine, C-reactive protein, and procalcitonin, need to be closely monitored during the treatment. When the change of a patient's condition is detected, a comprehensive clinical judgment needs to be made. When the secondary infection cannot be ruled out, qualified specimen need to be collected for testing by smear preparation, cultivation, nucleic acid, antigen and antibody, in order to determine the infectious agent as early as possible. Antibiotics can be empirically used in the following conditions: ① more expectoration, darker sputum color, especially yellow pus sputum; ② the rise of body temperature which is not due to exacerbation of the original disease; ③ the marked increase of white blood cells and/or neutrophils; ④ procalcitonin ≥ 0.5 ng/mL; ⑤ Exacerbation of oxygenation index or circulatory disturbance that are not caused by the viral infection; and the other conditions suspiciously caused by bacteria infections.

Some COVID-19 patients are at the risk of secondary fungal infections due to weakened cellular immunity caused by viral infections, the use of glucocorticoid and/or broad-spectrum antibiotics. It is necessary to do respiratory secretions microbiological detections such as smear preparation and cultivation for critically ill patients; and provide timely D-Glucose (G-test) and galactomannan (GM-test) of blood or bronchoalveolar lavage fluid for suspected patients.

It is necessary to be vigilant with possible invasive candidiasis infection and anti-fungal therapy. Fluconazole or echinocandin can be used in the following conditions: ① patients are given broad-spectrum antibiotics for seven days or more; ② patients have parenteral nutrition; ③ patients have invasive examination or treatment; ④ patients have positive candida culture in the specimen obtained from two body parts or more; ⑤ patients have significantly increased results of G-test.

It is necessary to be vigilant with possible invasive pulmonary aspergillosis. Anti-fungal therapy such as voriconazole, posaconazole, or echinocandin are considered to be used in the following conditions: ① patients are given glucocorticoid for seven days or more; ② patients have agranulocytosis; ③ patients have chronic obstructive pulmonary disease and aspergillus culture are tested positive in the specimen obtained from the airway; ④ patients have significantly increased results of GM-test.

IX. The Balance of Intestinal Microecology and Nutritional Support

Some COVID-19 patients have gastrointestinal symptoms (such as abdominal pain and diarrhea) due to direct viral infection of the intestinal mucosa or antiviral and anti-infective drugs. There has been report that the intestinal microecological balance is broken in COVID-19 patients, manifesting a significant reduction of the intestinal probiotics such as lactobacillus and bifidobacterium. Intestinal microecological imbalance may lead to bacterial translocation and secondary infection, so it is important to maintain the balance of intestinal microecology by microecological modulator and nutritional support.

1 Microecologics Intervention

(1) Microecologics can reduce bacterial translocation and secondary infection. It can increase dominant gut bacteria, inhibit intestinal harmful bacteria, reduce toxin production and reduce infection caused by gut microflora dysbiosis.

(2) Microecologics can improve the gastrointestinal symptoms of patients. It can reduce water in feces, improve fecal character and defecation frequency, and reduce diarrhea by inhibiting intestinal mucosal atrophy.

(3) The hospital with relevant resources can perform intestinal flora analysis. Therefore, the intestinal flora disturbance can be discovered early according to the results. Antibiotics can be adjusted timely and probiotics can be prescribed. These can reduce the chances of intestinal bacterial translocation and gut-derived infection.

(4) Nutrition support is an important means to maintain intestinal microecological balance. Intestinal nutrition support should be applied timely on the basis of effective evaluations of nutritional risks, gastroenteric functions, and aspiration risks.

2 Nutrition Support

The severe and critically ill COVID-19 patients who are in a state of severe stress are at high nutritional risks. Early evaluations of nutrition risk, gastrointestinal functions and aspiration risks, and timely enteral nutritional support are important to the patient's prognosis.

(1) Oral feeding is preferred. The early intestinal nutrition can provide nutritional support, nourish intestines, improve intestinal mucosal barrier and intestinal immunity, and maintain intestinal microecology.

(2) Enteral nutrition pathway. Severe and critically ill patients often harbor acute gastrointestinal damages, manifested as abdominal distension, diarrhea, and gastroparesis. For patients with tracheal intubation, intestinal nutrition tube indwelling is recommended for post-pyloric feeding.

(3) Selection of nutrient solution. For patients with intestinal damage, predigested short peptide preparations, which are easy for intestinal absorption and utilization, are recommended. For patients with good intestinal functions, whole-protein preparations with relatively high calories can be selected. For hyperglycemia patients, nutritional preparations which are beneficial to glycemic controlling are recommended.

(4) Energy supply. 25-30 kcal per kg body weight, the target protein content is 1.2-2.0 g/kg daily.

(5) Means of nutritional supply. Pump infusion of nutrients can be used at a uniform speed, starting with a low dosage and gradually increasing. When possible, the nutrients can be heated before feeding to reduce intolerance.

(6) The elderly patients who are at high aspiration risks or patients with apparent abdominal distention can be supported by parenteral nutrition temporarily. It can be gradually replaced by independent diet or enteral nutrition after their condition improves.

X. ECMO Support for COVID-19 Patients

COVID-19 is a novel, highly infectious disease primarily targeting pulmonary alveoli, which damages primarily the lungs of critically ill patients and leads to severe respiratory failure. For the application of extracorporeal membrane oxygenation (ECMO) in COVID-19 treatment, medical professionals need to pay close attention to the following: the time and means of intervention, anticoagulant and bleeding, coordination with mechanical ventilation, awake ECMO and the early rehabilitation training, strategy of handling for complications.

1 ECMO Intervention Timing

1.1 Salvage ECMO

In the state of mechanical ventilation support, measures such as lung protective ventilation strategy and prone position ventilation have been taken for 72 h. With the onset of one of the following conditions, salvage ECMO intervention needs to be considered.

- (1) $\text{PaO}_2/\text{FiO}_2 < 80$ mmHg (regardless of what the PEEP level is);
- (2) $\text{Pplat} \leq 30$ mmHg, $\text{PaCO}_2 > 55$ mmHg;
- (3) The onset of pneumothorax, air leakage $> 1/3$ tidal volume, duration > 48 h;
- (4) Circulation deterioration, the dosage of norepinephrine $> 1 \mu\text{g}/(\text{kg} \times \text{min})$;
- (5) Cardio-pulmonary resuscitation in vitro life support ECPR.

1.2 Replacement ECMO

When the patient is not suitable for long-term mechanical ventilation support, i.e., the patient is not able to obtain the expected results, ECMO replacement needs to be adopted immediately. With the onset of one of the following conditions, ECMO replacement needs to be considered.

- (1) Decreased lung compliance. After the pulmonary recruitment maneuver, the compliance of the respiratory system $< 10 \text{ mL}/\text{cmH}_2\text{O}$;
- (2) Persistent exacerbation of pneumomediastinum or subcutaneous emphysema. And the parameters of mechanical ventilation support cannot be reduced within 48 h, according to the estimation;
- (3) $\text{PaO}_2/\text{FiO}_2 < 100$ mmHg. And it cannot be improved by routine methods in 72 h.

1.3 Early Awake ECMO

Early awake ECMO can be applied to patients who have been supported by mechanical ventilation with the expected high parameters for more than 7 days and who meet the necessary conditions of awake ECMO. They might benefit from it. All the following conditions must be met:

- (1) The patient is in a clear state of consciousness and is fully compliant. He or she understands how ECMO works and its maintenance requirements;
- (2) The patient is not complicated with neuromuscular diseases;
- (3) Pulmonary damage score Murry > 2.5 ;
- (4) Few pulmonary secretions. The time interval between the two airway suction procedures > 4 h;
- (5) Stable hemodynamics. Vasoactive agents are not required for assistance.

2 Cathetering Methods

Because the ECMO supporting time for most COVID-19 patients is greater than 7 days, the seldinger method should be used as much as possible for the ultrasound guided peripheral catheter insertion, which reduces the bleeding damages and infection risks brought about by intravascular catheterization by venous angiostomy, especially for the early awake ECMO patients. Intravascular catheterization by venous angiostomy may be considered only for the patients with bad blood vessel conditions, or the patients whose catheterization cannot be identified and selected by ultrasound, or the patients whose seldinger technique failed.

3 Mode Selection

(1) The first choice for the patients of respiratory impairment is the V-V mode. The V-A mode should not be the first option just because of the possible circulation problems.

(2) For the respiratory failure patients complicated with cardiac impairment, $\text{PaO}_2/\text{FiO}_2 < 100$ mmHg, the V-A-V mode ought to be selected with the total flux > 6 L/min and $\text{V}/\text{A} = 0.5/0.5$ is maintained by current limiting.

(3) For the COVID-19 patients without severe respiratory failure but complicated with serious cardiovascular outcomes leading to cardiogenic shock, the V-A assisted by ECMO mode ought to be selected. But IPPV support is still needed and the awake ECMO should be avoided. the awake ECMO should be avoided.

4 Flux Set-value and Target Oxygen Supply

(1) The initial flux $> 80\%$ cardiac output (CO) with a self-cycling ratio $< 30\%$.

(2) $\text{SpO}_2 > 90\%$ is to be maintained. $\text{FiO}_2 < 0.5$ is supported by mechanical ventilation or the other oxygen therapy.

(3) To ensure the target flux, 22 Fr (24 Fr) vein access canula is the first choice for the patient with a body weight below (above) 80 kg.

5 Ventilation Setting

Normal ventilation maintenance by adjusting the sweep gas level:

(1) The initial air flow is set to be Flow: sweep gas = 1:1. The basic target is to maintain $\text{PaCO}_2 < 45$ mmHg. For the patients complicated with COPD, $\text{PaCO}_2 < 80\%$ basal level.

(2) The patient's spontaneous respiratory strength and respiratory rate (RR) should be maintained, with $10 < \text{RR} < 20$ and without chief complaint of breathing difficulty from the patient.

(3) The sweep gas setup of the V-A mode needs to ensure the 7.35-7.45 PH value of the bloodstream out of the oxygenator membrane.

6 Anti-Coagulation and Bleeding Prevention

(1) For the patients without active bleeding, without visceral bleeding, and with platelet count $> 50 \times 10^9/\text{L}$, the recommended initial heparin dosage is 50 U/kg.

(2) For the patients complicated with bleeding or with platelet count $< 50 \times 10^9/\text{L}$, the recommended initial heparin dosage is 25 U/kg.

(3) The activated partial thromboplastin time (aPPT) being 40—60 sec is proposed to be the target of anticoagulation maintenance dosage. The trend of D-dimer change should be considered at the same time.

(4) Heparin-free operation may be performed in the following circumstances: the ECMO support must continue but there is fatal bleeding or active bleeding that has to be controlled; whole heparin coated loop and catheterization with blood flow > 3 L/min. The recommend operation time < 24 hour. Replacement devices and consumables need to be prepared.

(5) Heparin resistance. Under some conditions of heparin usage, aPTT is not able to reach the standard and blood coagulation happens. In this case, the activity of plasma antithrombin III (ATIII) needs to be monitored. If the activity reduces, fresh frozen plasma needs to be supplemented to restore heparin sensitivity.

(6) Heparin induced thrombopenia (HIT). When HIT happens, we recommend to perform plasma exchange therapy, or to replace heparin with argatroban.

7 Weaning from ECMO and Mechanical Ventilation

(1) If a patient treated by V-V ECMO combined with mechanical ventilation satisfies the awake ECMO condition, we suggest to first try to remove the artificial airway, unless the patient has ECMO related complications, or the expected time of removal of all the assisting machines is less than 48 h.

(2) For a patient who has too much airway secretions that frequent artificial suction clearance is needed, who is expected to have a long-term mechanical ventilation support, who satisfies the conditions $\text{PaO}_2/\text{FiO}_2 > 150$ mmHg and time > 48 h, whose lung image changes for the better, and whose damages related to mechanical ventilation pressure have been controlled, the ECMO assistance may be removed. It is not recommended to keep ECMO intubation.





XI. Convalescent Plasma Therapy for COVID-19 Patients

Since Behring and Kitasato reported the therapeutic effects of diphtheria antitoxin plasma in 1891, plasma therapy has become an important means of pathogen immunotherapy for acute infectious diseases. The disease progression is rapid for severe and critically ill patients of an emerging infectious disease. In the early phase, the pathogens damage the target organs directly and then lead to severe immuno-pathological damage. The passive immune antibodies can effectively and directly neutralize the pathogens, which reduces the damage of the target organs and then block the subsequent immune-pathological damages. During multiple global pandemic outbreaks, WHO also emphasized that “convalescent plasma therapy is one of the most recommended potential therapies, and it has been used during other epidemic outbreaks”. Since the outbreak of COVID-19, the initial mortality rate was rather high due to the lack of specific and effective treatments. As mortality rate is an important metric that the public concerns, clinic treatments which can reduce the fatality rate of critical cases effectively are key to avoid public panic. As a provincial-level hospital in Zhejiang province, we have been responsible to treat the patients from Hangzhou and the critically ill patients of the province. There are abundant potential convalescent plasma donors and critically ill patients who need convalescent plasma treatment in our hospital.

1 Plasma collection

In addition to the common requirements of blood donation and procedures, the following details should be noted.

1.1 Donors

At least two weeks after recovery and being discharged (the nucleic acid test of the sample taken from the lower respiratory tract remains negative ≥ 14 days). $18 \leq \text{Age} \leq 55$. The body weight > 50 kg (for male) or > 45 kg (for female). At least one week since last glucocorticoid usage. More than two weeks since last blood donation.

1.2 Collection Method

Plasmapheresis, 200-400 mL each time (based on medical consultation).

1.3 Post-Collection Testing

In addition to the general quality test and the test of blood-borne disease, the blood samples need to be tested for:

- (1) Nucleic acid testing for SARS-CoV-2;
- (2) 160-fold dilution for the qualitative test of SARS-CoV-2 specific IgG and IgM detection; or 320-fold dilution for the qualitative test of whole antibody detection. If possible, keep > 3 mL plasma for the viral neutralization experiments.

The following should be noted. During the comparison of virus neutralization titer and luminescent IgG antibody quantitative detection, we found that the present SARS-CoV-2 specific IgG antibody detection does not fully demonstrate the actual virus neutralization capability of the plasma. Therefore, we suggested the virus neutralization test as the first choice, or test the overall antibody level with the 320-fold dilution of the plasma.

2 Clinical Use of the Convalescent Plasma

2.1 Indication

- (1) Severe or critically ill COVID-19 patients tested positive in respiratory tract test;
- (2) The COVID-19 patients who are not severe or critically ill, but in a state of immunity suppression; or have low CT values in the virus nucleic acid testing but with a rapid disease progression in the lungs.

Note: In principle, the convalescent plasma should not be used on COVID-19 patients with disease course exceeding three weeks. But in clinical applications, we found that the convalescent plasma therapy is effective for patients with a disease course exceeding three weeks and whose virus nucleic acid tests continuously to show positive from respiratory tracts specimen. It can speed up virus clearance, increase the numbers of the plasma lymphocytes and NK cells, reduce the level of plasma lactic acid, and improve renal functions.

2.2 Contraindication

- (1) Allergy history of plasma, sodium citrate and methylene blue;
- (2) For patients with history of autoimmune system diseases or selective IgA deficiency, the application of convalescent plasma should be evaluated cautiously by clinicians.

2.3 Infusion plan In general, the dosage of convalescent plasma therapy is ≥ 400 mL for one infusion, or ≥ 200 mL per infusion for multiple infusions.

XII. TCM Classification Therapy to Improve Curative Efficacy

1 Classification and Stage

COVID-19 can be divided into early, middle, critical and recovery stages. At the early

stage, the disease has two main types: “wet lungs” and “external cold and internal heat.” The middle stage is characterized by “intermittent cold and heat.” The critical stage is characterized by “internal block of epidemic toxin.” The recovery stage is characterized by “qi deficiency in lung-spleen.” The disease initially belongs to wet lung syndrome. Due to fever, both intermittent cold and heat treatments are recommended. In the middle stage, cold, dampness, and heat coexist, belonging to “cold-heat mixture” in terms of TCM. Both cold and heat therapy should be considered. According to the theory of TCM, heat should be treated with cold drugs. But cold drugs impair Yang and lead to a cold spleen and stomach and cold-heat mixture in the middle-Jiao. Therefore, in this stage both cold and heat therapies should be considered. Because cold-heat symptoms are commonly seen in COVID-19 patients, the cold-heat therapy is better than other approaches.

2 Therapy Based on Classification

(1) Wet lungs Ephedra Herb 6 g, Semen Armeniacae Amarumg 10 g, Coix Seed 30 g, Liquoric Root 6 g, Baical Skullcap Root 15 g, Huoxiang 10 g, Reed Rhizome 30 g, Cyrtomium Rhizome 15 g, Indian Buead 20 g, Chinese Atractylodes Rhizome 12 g, Official Magnolia Bark 12 g.

(2) External cold and internal heat

Herba Ephedrae 9 g, Raw Gypsum Fibrosum 30 g, Semen Armeniacae Amarumg 10 g, Liquoric Root 6 g, Baical Skullcap Root 15 g, Pericarpium Trichosanthis 20 g, Fructus Aurantii 15 g, Official Magnolia Bark 12 g, Tripterospermum Cordifolium 20 g, White Mulberry Root-bark 15 g, Pinellia Tuber 12 g, Indian Buead 20 g, Platycodon Root 9 g.

(3) Intermittent cold-heat

Pinellia Tuber 12 g, Baical Skullcap Root 15 g, Golden Thread 6 g, Dried Ginger 6 g, Chinese Date 15 g, Kudzuvine Root 30 g, Costustoot 10 g, Indian Buead 20 g, Thunberg Fritillary Bulb 15 g, Coix Seed 30 g, Liquoric Root 6 g.

(4) Internal block of epidemic toxin

Use cheongsimhwan for treatment.

(5) Qi deficiency of lung and spleen

Membranous Milkvetch Root 30 g, Pilose Asiabell Root 20 g, Roasted Largehead Atractylodes Rhizome 15 g, Indian Buead 20 g, Fructus Amomi 6 g, Siberian Solomonseal Rhizome 15 g, Pinellia Tuber 10 g, Tangerine Peel 6 g, Wingde Yan Rhizome 20 g, Semen Nelumbinis 15 g, Chinese Date 15 g.

Patients in different stages should take different approaches. One dose per day. Boil the medicine in water. Take it every morning and evening.

XIII. Drug Use Management of COVID-19 Patients

COVID-19 patients are often complicated with underlying diseases receiving multiple types of drugs. Therefore, we should pay more attention to the adverse drug reactions and drug interactions so as to avoid drug-induced organ damage and improve the success rate of treatment.

Table 1 The range of concentrations and points for attention of the common TDM drugs for the COVID-19 patients

Drug names	Time points of blood collection	The range of concentrations	Principles of dosage adjustment
lopinavir/ ritonavir	(peak) 30 min after drug administration (trough) 30 min before drug administration	lopinavir: (trough) > 1 µg/mL (peak) < 8.2 µg/mL	Correlated with drug efficacy and side effects.
imipenem	10 min before the drug administration	1~8 µg/mL	Interpretation and adjust the plasma drug concentration based on MIC of the pathogen testing
meropenem	10 min before the drug administration	1~16 µg/mL	
vancomycin	30 min before the drug administration	10~20 mg/L (15~20 mg/L for the severe MRSA infection)	The trough concentration correlates with the failure rate of anti-infective therapy and renal toxicity. When the concentration is overly high, reduction of drug frequency or single dose is required.
linezolid	30 min before the drug administration	2~7 µg/mL	The trough concentration correlates with myelosuppression adverse reactions. The blood routine test needs to be closely monitored.
voriconazol	30 min before the drug administration	1~5.5 µg/mL	The trough concentration correlates with the therapeutic efficacy and adverse reactions such as impaired liver function.

3 Paying attention to the potential drug interactions

Antiviral drugs such as lopinavir/ritonavir are metabolized through the enzyme CYP3A in the liver. When patients receiving concomitant medications, the potential drug interactions need to be carefully screened. Table 2 shows interactions between antiviral drugs and common drugs for underlying diseases.

Table 2 Interactions between antiviral drugs and common drugs for underlying

Drug names	Potential interactions	Contraindication in combined medication
lopinavir/ ritonavir	When combined with drugs associated with CYP3A metabolism (e.g., statins, immunosuppressors such as tacrolimus, voriconazole), the plasma concentration of the combined drug may increase; leading to 153%, 5.9 folds, 13 folds increase of the AUC of rivaroxaban, atorvastatin, midazolam, respectively. Pay attention to clinical symptoms and apply the TDM.	Combined use with amiodarone (fatal arrhythmia), quetiapine (severe coma), simvastatin (rhabdomyolysis) is prohibited.
darunavir/ cobicistat	When combined with drugs associated with CYP3A and/or CYP2D6 metabolism, the plasma concentration of the combined drugs may increase. See lopinavir/ ritonavir.	See lopinavir/ritonavir.
arbidol	It interacts with CYP3A4, UGT1A9 substrates, inhibitors, and inducers.	—
fapilavir	① Theophyllinum increases the bioavailability of fapilavir. ② It increases the bioavailability of acetaminophen by 1.79 folds. ③ Its combination with pyrazinamide increases the plasma uric acid level. ④ Its combination with repaglinide increases the plasma repaglinide level.	—
chloroquine phosphate	—	Prohibit to combine with the drugs that may lead to the prolonged Q-T interval (such as moxifloxacin, azithromycin, amiodarone, etc.).

Note: “—” : no relevant data; TDM: therapeutic drug monitoring; AUC: area under the curve; UGT1A9: uridine diphosphate glucosidase 1A9.

4 Avoiding medical damage in special populations

Special populations include pregnant women, patients with hepatic and renal insufficiency, patients supported by mechanical ventilation, patients under continuous renal replacement therapy (CRRT) or, extracorporeal membrane oxygenation (ECMO), etc. The following aspects need to be noted during drug administration.

(1) Pregnant women

Lopinavir/ritonavir tablets could be used. Favipiravir and chloroquine phosphate are prohibited.

(2) Patients with hepatic insufficiency Drugs that are excreted unchanged through the kidney are preferred, such as penicillin and cephalosporins, etc.

(3) Patients with renal insufficiency (including those on hemodialysis)

Drugs that are metabolized through the liver or excreted through the liver-kidney double channels are preferred, such as linezolid, moxifloxacin, ceftriaxone, etc.

(4) Patients under CRRT for 24h For vancomycin, the recommended regimen is: loading dose 1 g and maintenance dose 0.5 g, q12h. For imipenem, the maximum daily dosage should not exceed 2 g.



XIV. Psychological Intervention with COVID-19 Patients

1 The psychological stress and symptoms of COVID-19 patients

Confirmed COVID-19 patients often have symptoms such as regret and resentment, loneliness and helplessness, depression, anxiety and phobia, irritation and sleep deprivation. Some patients may have panic attacks. Psychological evaluations in the isolated wards demonstrated that, about 48% of confirmed COVID-19 patients manifested psychological stress during early admission, most of which were from their emotional response to stress. The percentage of delirium is high among the critically ill patients. There is even a report of encephalitis induced by the SARS-CoV-2 leading to psychological symptoms such as unconsciousness and irritability.

2 Establishing a dynamic mechanism for evaluation and warning of psychological crisis

Patients' mental states (individual psychological stress, mood, sleep quality, and pressure) should be monitored every week after admission and before discharge. The self-rating tools include: Self-Reporting Questionnaire 20 (SRQ-20), Patient Health Questionnaire 9 (PHQ-9) and Generalized Anxiety Disorder 7 (GAD-7). The peer-rating tools include: Hamilton Depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), Positive and Negative Syndrome Scale (PANSS). In such a special environment as the isolated wards, we suggest that patients should be guided to complete the questionnaires through their cell phones. The doctors can interview and perform scale assessing through face-to-face or online discussion.

3 Intervention and treatment based on the assessment

3.1 Principles of intervention and treatment

For mild patients, psychological intervention is suggested. Psychological self-adjustment includes breathing relaxation training and mindfulness training. For moderate to severe patients, intervention and treatment by combining medication and psychotherapy are suggested. New antidepressants, anxiolytics, and benzodiazepines can be prescribed to improve the patients' mood and sleep quality. The second generation antipsychotics such as olanzapine and quetiapine can be used to improve psychotic symptoms such as illusion and delusion.

3.2 The recommendation of psychotropic medications in elderly patients

Middle-aged or elderly COVID-19 patients' medical situations are often complicated by physical diseases such as hypertension and diabetes. Therefore, when selecting psychotropic medications, the drug interactions and their effects on respiration must be fully considered. We recommend using citalopram, escitalopram, etc. to improve depression and anxiety symptoms; benzodiazepines such as estazolam, alprazolam, etc. to improve anxiety and sleep quality; olanzapine, quetiapine, etc. to improve psychotic symptoms.

XV. Rehabilitation Therapy for COVID-19 Patients

Severe and critically ill patients suffer from different degrees of dysfunction, especially respiratory insufficiency, dyskinesia and cognitive impairment, during both acute and recovery stages.

1 Rehabilitation therapy for severe and critically ill patients

The goal of early rehabilitation intervention is to reduce breathing difficulties, relieve symptoms, ease anxiety and depression and lower the incidence of complications. The process of early rehabilitation intervention is: rehabilitation assessment - therapy - reassessment.

1.1 Rehabilitation assessment

Based on general clinical assessment, especially functional evaluation, including respiration, cardiac status, motion and ADL should be emphasized. Focus on respiratory rehabilitation assessment, which includes the evaluation of thoracic activity, diaphragm activity amplitude, respiratory pattern and frequency, etc.

1.2 Rehabilitation therapy

The rehabilitation therapy of severe or critically ill COVID-19 patients mainly includes position management, respiratory training, and physical therapy.

(1) Position management. Postural drainage may reduce the influence of sputum on the respiratory tract, which is especially important to improve the patient's V/Q. Patients must learn to tip themselves into a position which allows gravity to assist in draining excretion from lung lobes or lung segments. For patients using sedatives and suffering from consciousness disturbance, a standing-up bed or the bed head elevation (30°-45°-60°) may be applied if the patient's condition permits. Standing is the best body position for breathing in a resting state, which can effectively increase the patient's respiratory efficiency and maintain lung volume. As long as the patient feels good, let the patient take a standing position and gradually increase the time standing.

(2) Respiratory exercise. Exercise can fully expand the lungs, help the excretions from pulmonary alveoli and airway expel into the large airway so that sputum would not accumulate at the bottom of the lungs. It increases the vital capacity and enhances lung function. Deep-slow breathing and chest expansion breathing combined with shoulder expansion are the two major techniques of respiratory exercises.

① Deep-slow breathing: while inhaling, the patient should try his/her best to move the diaphragm actively. The breathing should be as deep and slow as possible to avoid the reduction of respiratory efficiency caused by fast-shallow breathing. Compared with thoracic breathing, this kind of breathing needs less muscle strength but has better tidal volume and V/Q value, which can be used to adjust breathing when experiencing short of breath.

② Chest expansion breathing combined with shoulder expansion: Increase pulmonary ventilation. When taking a deep-slow breath, one expands his/her chest and shoulders while inhaling; and moves back his/her chest and shoulders while exhaling. Due to the special pathological factors of viral pneumonia, suspending breathing for a long time should be avoided in order not to increase the burden of respiratory function, and the heart, as well as oxygen consumption. Meanwhile, avoid moving too fast. Adjust the respiratory rate at 12-15 times/min.

(3) Active cycle of breathing techniques. It can effectively remove bronchus excretion and improve lung function without exacerbation of hypoxemia and airflow obstruction. It consists of three stages (breathing control, thoracic expansion and exhalation). How to form a cycle of breathing should be developed according to the patient's condition.

(4) Positive expiratory pressure trainer. The pulmonary interstitium of COVID-19 patients has been severely damaged. In mechanical ventilation, low pressure and low tidal volume are required to avoid damages to the pulmonary interstitium. Therefore, after the removal of mechanical ventilation, positive expiratory pressure trainer can be used to help the movement of excretions from the low volume lung segments to the high-volume segments, lowering the difficulty of expectoration. Expiratory positive pressure can be generated through air flow vibration, which vibrates the airway to achieve airway supporting. The excretions can then be removed as the high-speed expiratory flow moves the excretions.

(5) Physical therapy. This includes ultrashort wave, oscillators, external diaphragm pacemaker, electrical muscle stimulation, etc.

XVI. Lung Transplantation in Patients with COVID-19

Lung transplantation is an effective treatment approach for final-stage chronic lung diseases. However, it is rarely reported that lung transplantation has been performed to treating acute infectious lung diseases. Based on current clinical practice and results, FAHZU summarized this chapter as a reference for medical workers. In general, following the principles of exploration, doing the best to save life, highly selective and high protection, if lung lesions are not significantly improved after adequate and reasonable medical treatment, and the patient is in critical condition, lung transplantation could be considered with other evaluations.

1 Pre-transplantation assessment

(1) Age: It is recommended that the recipients are not older than 70. Patients over 70 years old are subject to careful evaluation of other organ functions and postoperative recovery capability.

(2) The course of the disease: There is no direct correlation between the length of the disease course and the severity of the disease. However, for patients with short disease courses (fewer than 4-6 weeks), a full medical assessment is recommended to evaluate whether adequate medication, ventilator assistance, and ECMO support have been provided.

(3) Lung function status: Based on the parameters collected from lung CT, ventilator, and ECMO, it is necessary to evaluate whether there is any chance of recovery.

(4) Functional assessment of other major organs: a. Evaluation of the consciousness status of patients in critical condition using brain CT scan and electroencephalography is crucial, as most of them would have been sedated for an extended period; b. Cardiac assessments, including electrocardiogram and echocardiography that focus on right heart size, pulmonary artery pressure and left heart function, are highly recommended; c. The levels of serum creatinine and bilirubin should also be monitored; for patients with liver failure and renal failure, they should not be subjected to lung transplantation until the functions of the liver and kidney are recovered.

(5) The nucleic acid test of COVID-19: The patient should be tested negative for at least two consecutive nucleic acid tests with a time interval longer than 24 hours. Given the increased incidents of COVID-19 test result returning from negative to positive after treatment, it is recommended to revise the standard to three consecutive negative results. Ideally, negative results should be observed in all body fluid samples, including blood, sputum, nasopharynx, broncho-alveolar lavage, urine, and feces. Considering the difficulty in operation, however, at least the testing of sputum and broncho-alveolar lavage samples should be negative.

(6) Assessment of infection status: With the extended in-patient treatment, some COVID-19 patients may have multiple bacterial infections, and thus a full medical assessment is recommended to evaluate the situation of infection control, especially for multidrug-resistant bacterial infection. Moreover, post-procedure antibacterial treatment plans should be formed to estimate the risk of post-procedure infections.

(7) The preoperative medical assessment process for lung transplantation in COVID-19 patients: a treatment plan proposed by the ICU team → multidisciplinary discussion → comprehensive medical evaluation → analysis and treatment of relative contraindications → pre-habilitation before lung transplantation.

2 Contraindications

Please refer to The 2014 ISHLT Consensus: A consensus document for the selection of lung transplantation candidates issued by the International Society for Heart and Lung Transplantation (updated in 2014).

XVII. Discharge Standards and Follow-up Plan for COVID-19 Patients

1 Discharge standards

- (1) Body temperature remains normal for at least 3 days (ear temperature is lower than 37.5 °C);
- (2) Respiratory symptoms are significantly improved;
- (3) The nucleic acid is tested negative for respiratory tract pathogen twice consecutively (sampling interval more than 24 hours); the nucleic acid test of stool samples can be performed at the same time if possible;
- (4) Lung imaging shows obvious improvement in lesions;
- (5) There is no comorbidities or complications which require hospitalization;
- (6) SpO₂ > 93% without assisted oxygen inhalation;
- (7) Discharge approved by multi-disciplinary medical team.

2 Medication after discharge

Generally, antiviral drugs are not necessary after discharge. Treatments for symptoms can be applied if patients have mild cough, poor appetite, thick tongue coating, etc. Antiviral drugs can be used after discharge for patients with multiple lung lesions in the first 3 days after their nucleic acid are tested negative.

3 Home isolation

Patients must continue two weeks of isolation after discharge. Recommended home isolation conditions are:

- ① Independent living area with frequent ventilation and disinfection;
- ② Avoid contacting with infants, the elderly and people with weak immune functions at home;
- ③ Patients and their family members must wear masks and wash hands frequently;
- ④ Body temperature are taken twice a day (in the morning and evening) and pay close attention to any changes in the patient's condition.

4 Follow-up

A specialized doctor should be arranged for each discharged patient's follow-ups. The first follow-up call should be made within 48 hours after discharge. The outpatient follow-up will be carried out 1 week, 2 weeks, and 1 month after discharge. Examinations include liver and kidney functions, blood test, nucleic acid test of sputum and stool samples, and pulmonary function test or lung CT scan should be reviewed according to the patient's condition. Follow-up phone calls should be made 3 and 6 months after discharge.

5 Management of patients tested positive again after discharge

Strict discharge standards have been implemented in our hospital. There is no discharged case in our hospital whose sputum and stool samples are tested positive again in our follow-ups. However, there are some reported cases that patients are tested positive again, after being discharged based on the standards of national guidelines (negative results from at least 2 consecutive throat swabs collected at an interval of 24 hours; body temperature remaining normal for 3 days, symptoms significantly improved; obvious absorption of inflammation on lung images). It is mainly due to sample collection errors and false negative testing results. For these patients, the following strategies are recommended:

- (1) Isolation according to the standards for COVID-19 patients.
- (2) Continuing to provide antiviral treatment which has been proved to be effective during prior hospitalization.
- (3) Discharge only when improvement is observed on lung imaging and the sputum and stool are tested negative for 3 consecutive times (with an interval of 24 hours).
- (4) Home isolation and follow-up visits after discharge in accordance with the requirements mentioned above.

Part Three Nursing

I. Nursing Care for Patients Receiving High-Flow Nasal Cannula (HFNC) Oxygen Therapy

1 Assessing

Provide detailed information of the HFNC oxygen therapy to get the patient's cooperation before implementation. Use low dose sedative with close monitoring if necessary. Choose a proper nasal catheter based on the diameter of the patient's nasal cavity. Adjust the head strap tightness and use decompression plaster to prevent device-related pressure injuries on the facial skin. Maintain the water level in the humidifier chamber. Titrate the flow rate, the fraction of inspired oxygen (FiO_2), and the water temperature based on the patient's respiratory demands and tolerance.

2 Monitoring

Report to the attending physician to seek medical decision of replacing HFNC by mechanical ventilation if any of the followings occur: hemodynamic instability, respiratory distress evidenced by obvious contraction of accessory muscles, hypoxemia persists despite oxygen therapy, deterioration of consciousness, the respiratory rate > 40 breaths per minute continuously, significant amount of sputum.

3 Treatment of Secretions

Patients' drool, snot, and sputum should be wiped with tissue paper, be disposed in a sealed container with chlorine-containing disinfectant (2500 mg/L). Alternatively, secretions can be removed by oral mucus extractor or suctioning tube and be disposed in a sputum collector with chlorine-containing disinfectant (2500 mg/L).

II. Nursing Care for Patients with Mechanical Ventilation

1 Intubation Procedures

The number of the medical staff should be limited to the minimum number that can ensure the patient's safety. Wear powered air-purifying respirator as PPE. Before intubation, perform administration of sufficient analgesia and sedative, and use muscle relaxant if necessary. Closely monitor the hemodynamic response during intubation. Reduce movement of staff in the ward, continuously purify and disinfect the room with plasma air purification technology for 30 min after completion of intubation.

III. Daily Management and Monitoring of ECMO (Extra Corporeal Membrane Oxygenation)

- 1 **ECMO equipment should be managed by ECMO perfusionists and the following items should be checked and recorded every hour:** Pump flow rate/rotation speed; blood flow; oxygen flow; oxygen concentration; ensuring that the temperature controller is flowing; temperature setting and actual temperature; preventing clots in circuit; no pressure to the cannulae and the circuit tubing is not kinked, or no “shaking” of ECMO tubes; patient's urine color with special attention to red or dark brown urine; pre & post membrane pressure as required by the doctor.
- 2 **The following items during every shift should be monitored and recorded:** Check the depth and fixation of cannula to ensure that the ECMO circuit interfaces are firm, the water level line of the temperature controller, the power supply of the machine and the connection of the oxygen, the cannula site for any bleeding and swelling; measure leg circumference and observe whether the lower limb on the operation side is swollen; observe lower limbs, such as dorsalis pedis artery pulse, skin temperature, color, etc.
- 3 **Daily monitoring:** Post membrane blood gas analysis.
- 4 **Anticoagulation management:** The basic goal of ECMO anticoagulation management is to achieve a moderate anticoagulation effect, which ensures that certain coagulation activity under the premise of avoiding excessive activation of coagulation. That is to maintain the balance among anticoagulation, coagulation and fibrinolysis. The patients should be injected with heparin sodium (25-50 IU/kg) at the time of intubation and maintained with heparin sodium (7.5-20 IU/kg/h) during the pump flow period. The dosage of heparin sodium should be adjusted according to APTT results which should be held between 40-60 seconds. During the anticoagulation period, the number of skin punctures should be reduced as less as possible. Operations should be taken gently. The status of bleeding should be observed carefully.
- 5 Implement the "ultra-protective lung ventilation" strategy to avoid or reduce the occurrence of ventilator-related lung injury. It is recommended that the initial tidal volume is < 6 mL/kg and the intensity of spontaneous breathing is retained (breathing frequency should be between 10-20 times/min).
- 6 Closely observe the vital signs of patients, maintain MAP between 60-65 mmHg, CVP < 8 mmHg, SpO₂ > 90%, and monitor the status of urine volume and blood electrolytes.
- 7 Transfuse through the post membrane, avoiding infusion of fat emulsion and propofol.
- 8 According to the monitoring records, evaluate the ECMO oxygenator function during every shift.

IV. Nursing Care of ALSS (Artificial Liver Support System)

ALSS nursing care is mainly divided into two different periods: nursing care during treatment and intermittent care. Nursing staff should closely observe the conditions of patients, standardize the operating procedures, focus on key points and deal with complications timely in order to successfully complete ALSS treatment.

1 Nursing Care during Treatment

It refers to nursing during each stage of ALSS treatment. The overall operation process can be summarized as follows: operator's own preparation, patient evaluation, installation, pre-flushing, running, parameter adjustment, weaning and recording. The following are the key points of nursing care during each stage:

(1) Operator's own preparation

Fully adhere to Level III or even more strict protective measures.

(2) Patient assessment

Assess the patient's basic conditions, especially allergy history, blood glucose, coagulation function, oxygen therapy, sedation (for sober patients, pay attention to their psychological state) and catheter function status.

(3) Installation and pre-flushing

Use consumables with closed-loop management while avoiding the exposure to patient's blood and body fluids. The corresponding instruments, pipelines and other consumables should be selected according to the planned treatment mode. All basic functions and characteristics of the consumables should be familiarized.

(4) Running

It is recommended that the initial blood draw speed is ≤ 35 mL/min to avoid low blood pressure which might be caused by high speed. Vital signs should be monitored as well.

(5) Parameter Adjustment

When the patient's extracorporeal circulation is stable, all treatment parameters and alarm parameters should be adjusted according to the treatment mode. A sufficient amount of anticoagulant is recommended in the early stage and the anticoagulant dose should be adjusted during the maintenance period according to different treatment pressure.

(6) Weaning

Adopt "liquid gravity combined recovery method"; the recovery speed ≤ 35 mL/min; after weaning, medical waste should be treated in accordance to the SARS-Cov-2 infection prevention and control requirements and the treatment room and instruments should be cleaned and disinfected as well.

(7) Recording

Make accurate records of the patient's vital signs, medication and treatment parameters for ALSS and take notes on special conditions.

VI. General Care

1 Monitoring

Patient vital signs should be continuously monitored, especially changes in consciousness, respiration rate and the oxygen saturation. Observe symptoms such as cough, sputum, chest tightness, dyspnea, and cyanosis. Monitor arterial blood gas analysis closely. Timely recognition of any deterioration to adjust strategies of oxygen therapy or to take urgent response measures. Pay attention to ventilator associated lung injury (VALI) when under high positive end-expiratory pressure (PEEP) and high-pressure support. Closely monitor changes in airway pressure, tidal volume and respiratory rate.

2 Aspiration Prevention

(1) Gastric retention monitor: perform continuous post-pyloric feeding with a nutrition pump to reduce gastroesophageal reflux. Evaluate gastric motility and gastric retention with ultrasound if possible. Patient with normal gastric emptying are not recommended for routine assessment;

(2) Evaluate gastric retention every 4 hours. Re-infuse the aspirate if the gastric residual volume is < 100 mL; otherwise, report to the attending physician;

(3) Aspiration prevention during patient transportation: before transportation, stop nasal feeding, aspirate the gastric residues and connect the gastric tube to a negative pressure bag. During transportation, raise the patient's head up to 30°;

(4) Aspiration prevention during HFNC: Check the humidifier every 4 hours to avoid excessive or insufficient humidification. Remove any water accumulated in the tubing promptly to prevent cough and aspiration caused by the accidental entry of condensation into the airway. Keep the position of the nasal cannula higher than the machine and tubes. Promptly remove condensation in the system.

3 Implement strategies to prevent catheter-related bloodstream infection and catheter-related urinary tract infection.

4 Prevent pressure-induced skin injuries, including device-related pressure-induced injuries, incontinence-associated dermatitis and medical adhesive-related skin injuries. Identify patients at a high risk with the Risk Assessment Scale and implement preventive strategies.

5 Assess all patients upon admission and when their clinical conditions change with the VTE risk assessment model to identify those who are at a high risk and implement preventive strategies. Monitor coagulation function, D-dimer levels and VTE-related clinical manifestations.

6 Assist eating for patients who are weak, short of breath or those with an obvious fluctuating oxygenation index. Intensify oxygenation index monitoring on these patients during meals. Provide enteral nutrition at early stages for those who are unable to eat by mouth. During each shift, adjust the enteral nutrition rate and quantity according to the tolerance of enteral nutrition.

Appendix

I. Medical Advice Example for COVID-19 Patients

1 Medical Advice of Mild COVID-19 Cases

1.1 Ordinary

- Air isolation, blood oxygen saturation monitoring, oxygen therapy with nasal cannula

1.2 Examinations

- 2019 Novel Coronavirus RNA Detection (Three Sites) (Sputum) qd
- 2019 Novel Coronavirus RNA Detection (Three Sites) (Feces) qd
- Blood routine, biochemical profile, urine routine, stool routine + OB, coagulation function + D dimer, blood gas analysis + lactic acid, ASO + RF + CPR + CCP, ESR, PCT, ABO + RH blood type, thyroid function, cardiac enzymes + quantitative assay of serum troponin, four routine items, respiratory virus test, cytokines, G/GM test, angiotensin converting enzyme
- Liver, gallbladder, pancreas and spleen ultrasound, echocardiography and lung CT scan

1.3 Medication

- Arbidol tablets 200 mg po tid
- Lopinavir/Ritonavir 2 tablets po q12h
- Interferon spray 1 spray pr. tid

3 Medical Advice of Severe COVID-19 Cases

3.1 Ordinary

- Air isolation, blood oxygen saturation monitoring, oxygen therapy with nasal cannula

3.2 Examinations

- 2019 Novel Coronavirus RNA Detection (Three Sites) (Sputum) qd
- 2019 Novel Coronavirus RNA Detection (Three Sites) (Feces) qd
- Blood routine, biochemical profile, urine routine, stool routine + OB, coagulation function + D dimer, blood gas analysis + lactic acid, ASO + RF + CPR + CCP, ESR, PCT, ABO + RH blood type, thyroid function, cardiac enzymes + quantitative assay of serum troponin, four routine items, respiratory virus test, cytokines, G/GM test, angiotensin converting enzyme
- Liver, gallbladder, pancreas and spleen ultrasound, echocardiography and lung CT scan

3.3 Medication

- Arbidol tablets 200 mg tid
- Lopinavir/Ritonavir 2 tablets po q12h
- Interferon spray 1 spray pr.nar tid
- NS 100 mL + methylprednisolone 40 mg ivgtt qd
- NS 100 mL + pantoprazole 40 mg ivgtt qd
- Caltrate 1 tablet qd
- Immunoglobulin 20 g ivgtt qd
- NS 100 mL + Ambroxol 30 mg ivgtt bid

4 Medical Advice of Critical COVID-19 Cases

4.1 Ordinary

Air isolation, blood oxygen saturation monitoring, oxygen therapy with nasal cannula

4.2 Examinations


- 2019 Novel Coronavirus RNA Detection (Three Sites) (Sputum) qd
- 2019 Novel Coronavirus RNA Detection (Three Sites) (Feces) qd
- Blood routine, ABO + RH blood type, urine routine, stool routine + OB, four routine items, respiratory virus test, thyroid function, electrocardiogram, blood gas analysis + electrolyte + lactic acid + GS, G/GM test, blood culture ONCE
- Blood routine, biochemical profile, coagulation function + D dimer, blood gas analysis + lactic acid, natriuretic peptide, cardiac enzyme, quantitative assay of serum troponin, immunoglobulin + complement, cytokine, sputum culture, CRP, PCT qd
- Blood glucose measurement q6h
- Liver, gallbladder, pancreas and spleen ultrasound, echocardiography and lung CT scan

4.3 Medication

- Arbidol tablets 200 mg po. tid
- Lopinavir/Ritonavir 2 tablets q12h (or darunavir 1 tablet qd)
- NS 10 mL + methylprednisolone 40 mg iv q12h
- NS 100 mL + pantoprazole 40 mg ivgtt qd
- Immunoglobulin 20 g ivgtt qd
- Thymic peptides 1.6 mg ih biw
- NS 10 mL + Ambroxol 30 mg iv bid
- NS 50 mL + isoproterenol 2 mg iv-vp once
- Human serum albumin 10 g ivgtt qd
- NS100 mL + piperacillin/tazobactam 4.5 ivgtt q8h
- Enteral nutrition suspension (Peptisorb liquid) 500 mL nasogastric feeding bid

II. Online Consultation Process for Diagnosis and Treatment

2.1 Online Consultation for Diagnosis and Treatment



Please feel free to contact us:
Email: zdyy6616@126.com, zyinternational@163.com

2.2 Online Doctors' Communication Platform

Instructions on the International Medical Expert Communication Platform of The First Affiliated Hospital, Zhejiang University School of Medicine




Figure1: Scan to Download DingTalk App



Figure 2: QR Code of FAHZU Communication Platform



Figure 3: User Guide

Note: Scan the QR code of Figure 3 to download user guide

Editorial Board

Editor-in-chief: LIANG Tingbo

Members: CAI Hongliu, CHEN Yu, CHEN Zuobing, FANG Qiang, HAN Weili, HU Shaohua, LI Jianping, LI Tong, LU Xiaoyang, QU Tingting, SHEN Yihong, SHENG Jifang, WANG Huafen, WEI Guoqing, XU Kaijin, ZHAO Xuehong, ZHONG Zifeng, ZHOU Jianying

References

1. National Health Commission and National Administration of Traditional Chinese Medicine of the People's Republic of China. Protocols for Diagnosis and Treatment of COVID-19 (7th Trial Version) [EB/OL].(2020-03-04)[2020-03-15].
<http://www.nhc.gov.cn/zyygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml> (in Chinese)
2. National Health Commission of the People's Republic of China. Protocols for Prevention and Control of COVID-19 (6th Version) [EB/OL].(2020-03-09)[2020-03-15].
<http://www.nhc.gov.cn/jkj/s3577/202003/4856d5b0458141fa9f376853224d41d7.shtml> (in Chinese)
3. Chinese Center for Disease Control and Prevention. Guidelines for Epidemiological Investigation of COVID-19 [EB/OL]. (in Chinese) (2020-03-09)[2020-03-15].
http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html
4. Chinese Center for Disease Control and Prevention. Guidelines for Investigation and Management of Close Contacts of COVID-19 Patients [EB/OL]. (in Chinese) (2020-03-09)[2020-03-15].
http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html
5. Chinese Center for Disease Control and Prevention. Technical Guidelines for COVID-19 Laboratory Testing [EB/OL]. (in Chinese) (2020-03-09)[2020-03-15].
http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html
6. Chinese Center for Disease Control and Prevention. Technical Guidelines for Disinfection of Special Sites [EB/OL]. (in Chinese) (2020-03-09)[2020-03-15].
http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html
7. Chinese Center for Disease Control and Prevention. Guidelines for Personal Protection of Specific Groups [EB/OL]. (in Chinese) (2020-03-09)[2020-03-15].
http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/jszl_11815/202003/t20200309_214241.html
8. Technical Guidelines for Prevention and Control of COVID-19, Part3: Medical Institutions, Local Standards of Zhejiang Province DB33/T 2241.3—2020. Hangzhou, 2020 (in Chinese)
9. Chinese Center for Disease Control and Prevention. Distribution of Novel Coronavirus Pneumonia [EB/OL]. (in Chinese) [2020-03-15].
<http://2019ncov.chinacdc.cn/2019-nCoV/>

10. Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern [J]. *Lancet* 2020;395(10223):470-473. doi: 10.1016/S0140-6736(20)30185-9.
11. China CDC has Detected Novel Coronavirus in Southern China Seafood Market of Wuhan [EB/OL]. (in Chinese) (2020-01-27)[2020-03-15].
http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html
12. National Health Commission of the People's Republic of China. Notification of Novel Coronavirus Pneumonia Temporarily Named by the National Health Commission of the People's Republic of China [EB/OL]. (in Chinese) (2020-02-07)[2020-03-15].
<http://www.nhc.gov.cn/mohwsbwstjxxzx/s2908/202002/f15dda000f6a46b2a1ea1377cd80434d.shtml>.
13. Gorbalenya AE, Baker SC, Baric RS, et al. Severe Acute Respiratory Syndrome-related Coronavirus- The Species and its Viruses, a Statement of the Coronavirus Study Group [J/OL]. *BioRxiv* 2020. doi:10.1101/2020.02.07.937862.
14. WHO. Novel Coronavirus(2019-nCoV) Situation Report-22 [EB/OL].(2020-02-11)[2020-03-15].
<https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/>
15. Bureau of Disease Control and Prevention, National Health Commission of the People's Republic of China. Novel coronavirus infection pneumonia is included in the management of notifiable infectious diseases [EB/OL]. (in Chinese) (2020-01-20)[2020-02-15].
<http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8d3f36701d49f33.shtml>
16. Chen Y, Liang W, Yang S, et al. Human Infections with the Emerging Avian Influenza A H7N9 virus from Wet Market Poultry: Clinical Analysis and Characterisation of Viral Genome [J]. *Lancet* 2013;381(9881):1916-1925. doi: 10.1016/S0140-6736(13)60903-4.
17. Gao HN, Lu HZ, Cao B, et al. Clinical Findings in 111 Cases of Influenza A (H7N9) Virus Infection [J]. *N Engl J Med* 2013;368(24):2277-2285. doi:10.1056/NEJMoa1305584.
18. Liu X, Zhang Y, Xu X, et al. Evaluation of Plasma Exchange and Continuous Veno-venous Hemofiltration for the Treatment of Severe Avian Influenza A (H7N9): a Cohort Study [J]. *Ther Apher Dial* 2015;19(2):178-184. doi:10.1111/1744-9987.12240.
19. National Clinical Research Center for Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases. Expert Consensus on Novel Coronavirus Pneumonia Treated with Artificial Liver Blood Purification System [J]. *Chinese Journal of Clinical Infectious Diseases* 2020;13. (in Chinese) doi:10.3760/cma.j.issn.1674-2397.2020.0003.
20. Weill D, Benden C, Corris PA, et al. A Consensus Document for the Selection of Lung Transplant Candidates: 2014—An Update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation [J]. *J Heart Lung Transplant* 2015;34(1):1-15. doi: 10.1016/j.healun.2014.06.014.



Overview of FAHZU

Founded in 1947, The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU), is the earliest affiliated hospital of Zhejiang University. With six campuses, it has now evolved into a medical center integrating health care, medical education, scientific research and preventative care. In terms of overall strength, FAHZU is ranked 14th in China.

As a large-size general hospital, it currently has over 6,500 employees, including academicians of the Chinese Academy of Engineering, National Distinguished Young Scholars and other outstanding talents. There is a total of 4,000 beds available to patients in FAHZU. Its main campus handled 5 million emergency and outpatient visits in 2019.

Over the years, FAHZU has successfully developed a number of renowned programs in organ transplantation, pancreatic diseases, infectious diseases, hematology, nephrology, urology, clinical pharmacy, etc. FAHZU helps many realize the radical resection of cancer and enjoy long-term survival. FAHZU is also an integrated provider of liver, pancreas, lung, kidney, intestine and heart transplantation. In the fight against SARS, H7N9 avian flu and COVID-19, it has gained rich experience and fruitful results. As a result, its medical professionals have published many articles in journals such as *New England Journal of Medicine*, *the Lancet*, *Nature* and *Science*.

FAHZU has been extensively engaged into overseas exchanges and collaboration. It has established partnerships with over 30 prestigious universities around the world. Productive achievements have also been accomplished through exchange of our medical experts and technologies with Indonesia, Malaysia and other countries.

Adhering to the core value of seeking truth with prudence, FAHZU is here to offer quality health care to everyone in need.



马云公益基金会
Jack Ma Foundation



浙江大学
ZHEJIANG UNIVERSITY



浙江大学医学院附属第一医院
THE FIRST AFFILIATED HOSPITAL, COLLEGE OF MEDICINE, ZHEJIANG UNIVERSITY
浙江省第一医院
THE FIRST HOSPITAL OF ZHEJIANG PROVINCE

Alibaba Cloud



AliHealth
阿里健康